Nitric Oxide Synthase Activity and its Modulation in the Treatment of Colorectal Cancer by Alam, Asim
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2015
Nitric Oxide Synthase Activity and its Modulation
in the Treatment of Colorectal Cancer
Asim Alam
Virginia Commonwealth University, alama4@vcu.edu
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biochemistry Commons, Cancer Biology Commons, and the Molecular Biology
Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/4064
  
  
 
© Asim Alam, 2015 
 
All Rights Reserved
  
  
 
Nitric Oxide Synthase Activity and its Modulation in the Treatment of 
Colorectal Cancer 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
 
 
by 
 
 
Asim Alam 
Bachelor of Science, University of California, San Diego 2008 
 
 
Ross B. Mikkelsen, PhD 
Professor and Vice Chair for Research, Department of Radiation Oncology 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
December 2, 2015
ii 
 
  
Acknowledgements 
First and foremost, I’d like to thank God for all the blessings I have received in life 
and to finally finish my dissertation work! 
There are a number of individuals who have helped me so far on this journey, 
none more important than my parents Muzaffar and Shakra Alam. Thank you for 
always supporting us and giving us the opportunity to study and grow up in 
America. Hopefully your sacrifices were worth it.  To my brothers Arfeen and 
Omair and sisters Mahza, Nisa and Hiba, thank you for being my best friends 
through all of my time growing up and now… and for leaving California for 
Richmond so we could be closer.   
Thank you  to my wife, Zayneb, who luckily for her hasn’t had to deal with my 
whole PhD experience, but has made this past year very easy for me to finish. 
Thank you for being understanding and loving especially when I am being 
difficult.  I am eternally gratefully to have met you. 
The past and present members of the Mikkelsen Lab: Drs. Robert Cardnell, Eric 
Howlett, Vasily Yakovlev, Chris Rabender and Master’s candidate Ninu Bruno. 
Thank you all for your support in teaching me techniques and answering my 
usually rudimentary questions. I am indebted to you all for all I have learned in 
the Mikkelsen Lab. Thank you also for being friends and keeping the lab a more 
friendly and social environment.  
Dr. Mikkelsen, thank you for being a very caring and motivating advisor. Thank 
you for letting me venture on my own with my projects, for discussing topics with 
me as an equal and for accepting me into the MD/PhD program.  We have not 
seen eye to eye on everything, but I appreciate how understanding you have 
been with me as a student and person.  You truly do care for the people in the 
lab more than just students or workers, but for us as individuals.  
A number of people have been instrumental in helping me finish my project: Dr. 
Gobalakrishna, Li Wang and Reed McDonagh from Dr. Zweit’s lab for FDG/PET 
imaging and AOM/DSS animal care.  Jason Beckta and Valerie Lab members for 
materials support and confocal imaging. Justin Sperlazza from Dr. Ginder’s Lab 
for help with lentiviral transfection and qPCR techniques.  Mike Waters from Dr. 
Kordula lab for TCGA data acquisition and analysis.  
Dr. Archer (retired), Sandra Sorrell and the MD/PhD program for giving me the 
opportunity to acquire both degrees. Thank you for taking a chance on me. 
iii 
 
  
Table of Contents 
Page 
 
 
Acknowledgements………………………………………………………………….   ii 
   Abbreviations………………………………………………………………………….vi 
Abstract…….………………………………………….……………………………….ix 
  Chapter 
1   Introduction…………………………...…………….……………...........1 
Colorecatal Cancer & Inflammation…………………………………………...1 
Nitric oxide generation and signaling……………...………………...2 
NOS modulation in inflammation…………………………………….7 
Implications of NOS uncoupling & ROS/RNS signaling….………..9 
Scope of the Dissertation……………………………………………14 
2 Recoupling NOS in vitro in colorectal tumor cells………………….16 
Materials and Methods……………………………………………….19 
 Chemicals and Reagents……………………………………..19 
 Cell Culture……………………………………………………..20 
 BH4:BH2 Measurements……………………………………..20 
 Cell Viability Assay (WST)…………………………………….22 
 Clonogenic Assay……………………………………………...22 
 Western Blot Analysis…………………………………………22 
 shRNA Lentiviral Transduction……………………………….23 
 LET/TCF Luciferase Assay…………………………………...24 
AKT Activity Assay…………………………………………….24 
iv 
 
  
Biotin Switch Assay……………………………………………24 
Results………………………………………………………………….26 
                   Sepiapterin raises BH4:BH2 ratio in colorectal tumor cells   
and decreases proliferation.……...………………………….26 
 
 SP decreases expression of β-catenin………………………30 
 GSK3β inhibition or knockdown abrogates SP’s effects..…36 
Discussion……………………………………………………………...41 
                     3    Recoupling NOS in vivo & Mechanisms of NOS uncoupling in                                           
    colorectal tumors…...……………………………………………….46 
 
Introduction…………………………………………………………….46 
DSS induced colitis and AOM induced cancer…………………….46 
Potential mechanisms of NOS uncoupling…..…………………….48 
BH4 synthesis and recycling…………..…………………………….50 
Materials and Methods………………………………………………..52 
  Mouse model of colitis and colorectal carcinoma…………..52 
 Western blot analysis………………………………………….53 
 Histopathological & Immunofluorescence Staining………...53 
 PET/FDG Image acquisition and analysis…………………..54 
 Separation of colonic epithelium from mesenchymal layer..55 
 RNA isolation and qPCR gene expression………………….56 
 mRNA analysis from matched patient samples……………..57 
  
Results………………………………………………………………….57 
SP raises BH4:BH2 ratio in vivo and decreases FDG uptake 
and tumor size………….……………………………………...57 
v 
 
  
SP leads to increased apoptosis and decreased β-catenin       
levels.. .………………………………………………………....63 
 
An oxidative environment & altered levels of biopterin 
metabolizing enzymes contribute to a decreased  
BH4:BH2ratio…………………………………………………..67 
 
   Discussion……………………………………………………………72 
4 Perspectives and Future Directions…………………………………....78 
Using NO, BH4 or SP as cancer therapeutics………………………78 
          Tumor revascularization using SP….………………………………..80 
Analysis of Human biopsy samples for biopterin metabolizing 
 Enzymes………….……………………………………………………. 85 
 
Literature Cited…………………………………………..………………….86 
 
    
    
 
 
 
 
 
 
 
 
 
 
vi 
 
  
ABBRREVIATIONS 
AOM    azoxymethane 
APC    adenomatous polyposis coli 
BH2    dihydrobiopterin 
BH4    tetrahydrobiopterin 
CAC    Colitis associated Colorectal Cancer 
cGMP    3,5 cyclic guanine monophosphate 
COX    Cyclooxygenase 
CRC    Colorectal Cancer 
DHFR    Dihydrofolate Reductase 
DSS    Dextran Sodium Sulfate 
EGFR    Epidermal Growth Factor Receptor 
eNOS    endothelial Nitric Oxide Synthase 
ERK 1/2    Extracellular Regulated Kinase 
FAP    Familial Adenomatous Polyposis  
FBS    Fetal Bovine Serrum 
[18F]-FDG   Fluorine-18-fluorodeoxyglucose 
GCH-1   GTP cyclohydrolase I 
GFRP    GCH-1 Feedback Regulating Protein 
GSK3    Glycogen Synthase Kinase 3 
GSNO   S Nitrosoglutathione 
GTP    Guanosine triphosphate 
HIF    Hypoxia Inducible Factor 
vii 
 
  
HPLC    High Performance Liquid Chromatography 
IBD    Inflammatory Bowel Disease 
i.p.    intraperitoneal 
IF    Immunofluorescence 
IHC    Immunohistochemical 
iNOS    inducible Nitric Oxide Synthase 
IP    immunoprecipitate 
IκB    Inhibitor of kappa B 
JAK    Janus Kinases 
L-NAME   N-Nitro-L-Arginine Methyl Ester 
L-NNA   NG-nitro-L-Arginine  
Luc    Luciferase 
MAPK    Mitogen Activated Protein Kinase 
MMP-7   Matrix metalloprotein-7 
MMTS   methylmethanethiosulfonate 
MTX    Methotrexate 
NADPH Nicotinamide Adenine dinucleotide phosphate-reduced 
NFκB    Nuclear Factor kappa B 
nNOS    neuronal Nitric Oxide Synthase 
NO    Nitric Oxide 
NOS    Nitric Oxide Synthase 
NSAID   Non-Steroidal Anti-Inflammatory Drugs     
O2-    Superoxide 
viii 
 
  
ONOO-   Peroxynitrite 
PDE    Phosphodiesterase 
Pen Step   Penicillin Streptomycin 
PET    Positron Emitted Topography 
PKG    cGMP dependent protein kinase 
PTP    Protein Tyrosine Phosphatase 
QDPR    Quinone Dihydropteridine Reductase 
RNS    Reactive Nitrogen Species 
ROR    Retinoid-related orphan receptor 
ROS    Reactive Oxygen Species 
SDS-Page Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
sGC    soluble guanylyl cyclase 
SOD    Superoxide Dismutase 
SP    Sepiapterin 
SPR or SR   Sepiapterin Reductase 
STAT    Signal Transducer and Activator of Transcription 
TAM    Tumor associated macrophage 
TGF    Transforming growth factor  
TNF    Tumor Necrosis Factor 
Treg    Regulatory T Cells 
VEGF    Vascular endothelial growth factor 
 
 
ix 
 
  
Abstract 
The American Cancer Society estimates more than 141,000 new cases of and about 50,000 
deaths from colorectal cancer every year. Treatment options include surgery, radiation 
therapy and targeted therapies such as anti-angiogenics. However, no therapies address 
the key driving factor of colorectal cancer: inflammation. It is well known that chronic 
inflammatory conditions such as Crohn’s Disease, ulcerative colitis, diabetes, obesity and 
cigarette smoking all elevate the risk of developing colorectal cancer. One of the hallmarks 
of chronic inflammation is the elevated levels of reactive oxygen/nitrogen species 
(ROS/RNS). A primary source of these ROS/RNS is uncoupled Nitric Oxide Synthase 
(NOS). Under non-inflammatory conditions NOS generates Nitric Oxide. However, in an 
inflammatory environment, such as the oxidative tumor microenvironment, NOS’s cofactor 
tetrahydrobiopterin (BH4) is oxidized to dihydrobiopterin (BH2). NOS bound to BH2 is said 
to be uncoupled and produces superoxide O2- and peroxynitrite (ONOO-). Previous work in 
our and other’s labs have shown that increased production of ROS/RNS leads to the 
activation of pro-inflammatory/proliferative molecules such as NFκB, Stat3, β-Catenin and 
Akt. NOS can be re-coupled by supplementing cells and animals with BH4 or its precursor 
Sepiapterin (SP). Herein we show that recoupling NOS with SP in HCT116, Caco-2 and 
HT29 cells, decreased tumor cell proliferation, increased β-Catenin degradation and 
decreased Akt activity. We also see increased tumor cell death measured by in vitro 
clonogenic assay, as well as decreased metabolic uptake in Azoxymethane/Dextran 
Sodium Sulfate (AOM/DSS) induced colorectal cancer in vivo measured by [18F]-
fluorodeoxyglucose ([18F]-FDG) positron emitted topography (PET) imaging. We believe by 
recoupling NOS both in vivo and in vitro we are modulating Wnt signaling via Akt and GSK-
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3β. Lastly, we conducted studies to determine a mechanistic explanation of how tumor cells 
maintain a decreased BH4:BH2 ratio.  
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Chapter 1: Introduction 
Background and Significance 
 
Colorectal Cancer and Inflammation 
The American Cancer Society estimates that there are more than 141,000 new 
cases and about 50,000 deaths from colorectal cancer (CRC) every year in the U.S. 
CRC is the third leading cause of cancer-related deaths in both men and women with 1 
in 20 Americans developing colorectal cancer in their lifetimes [1]. The 5 year survival 
rate for lesions discovered in early stages is greater than 70%, however for advanced or 
metastatic lesions the 5 year survival drops to less than 11%. Although the incidence 
and mortality rates have been slowly but steadily declining due to better screening 
guidelines, colorectal cancer is still a disease with significant mortality and morbidity [1]. 
Elucidation of the genetic and molecular mechanisms of colorectal tumor development 
coupled with increased screening has, in part, played a role in the decline of incidence 
and our understanding of tumor initiation. However, more research is needed to 
understand the progression and maintenance of colorectal cancer and for the 
development of new treatment options.  
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Many factors have been identified which increase the risk of developing 
colorectal cancer. Thus far, age has been shown to be the greatest risk factor of 
developing sporadic colorectal tumors [2]. Other risk factors include obesity, cigarette 
use, diet and inflammatory bowel diseases such as Ulcerative Colitis and Crohn’s 
Disease [3].  Although inherited genetic mutations such as those found in Familial 
Adenomatous Polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNCC) 
confer a 90 percent chance of developing tumors, combined these inherited genetic 
disorders account for only about 5% of CRC [4-6]. However the genetic alterations 
found in FAP and HNCC have been invaluable tools to elucidate the mechanisms of 
tumor initiation and progression in colorectal cancer.    
Patients with FAP disease have a germline mutation in one copy of the tumor 
suppressor gene, Adenomatous Polyposis Coli (APC). The second copy of the gene is 
typically mutated within the first 30 years of life resulting in multiple tumors [7]. APC is 
an inhibitor of β-catenin, the effector molecule which activates Wnt signaling. The Wnt 
signal pathways regulate cell adhesion, migration, apoptosis and chromosome 
segregation during mitosis [8]. Most sporadic tumors have somatic mutations in APC 
gene as well. The cascade of mutations and histopathological changes have been well 
characterized by the work of Drs. Vogelstein and Kinzler [9-12], summarized below. 
Mutations in the APC gene have been shown to occur at the earliest stage of carcinoma 
development, the aberrant crypt foci. Two hits to the APC gene are required for loss of 
function providing the mutated cells a selective advantage to grow clonally. The 
oncogene KRAS is mutated next. Interestingly, KRAS is also mutated in about 50% of 
sporadic CRC. The combination of loss of APC and activating mutation in KRAS leads 
3 
 
  
to clonal expansion and dysplasia, histologically termed an adenoma. It is postulated 
that other unknown oncogenes are also mutated in the subset of CRC tumors which do 
not show KRAS mutations to allow for adenoma formation. As the adenoma progresses 
to adenocarcinoma, further mutations in TP53 and SMAD2 and SMAD4 tumor 
suppressor genes appear [10, 13, 14]. TP53 mutations arise in greater than 75% of 
spontaneous CRC, however rarely in the benign early stages of disease. p53 is an 
important regulator of DNA damage repair and cell cycle regulation [15]. SMAD2/4 are 
transcription factors activated by TGF-β signaling. In colorectal epithelial cells TGF-β 
signaling is thought to inhibit growth and promote differentiation of these cells [16, 17]. 
This genetic model developed by Vogelstein and colleagues predicts a minimum of 7 
genetic mutations to initiate a polyp and progress to carcinoma stage [9]. 
Wnt signaling is a critical regulator of normal cell turn over in healthy colonic 
epithelial cells. However, in over 90% of spontaneous CRC activation mutations in Wnt 
signaling have been found in the early stages of development leading to malignancy. 
The major effector of Wnt signaling is β-Catenin. β-Catenin is an important regulator of 
cell growth in normal and malignant colonic epithelial cells.  The most common 
activating mutation of Wnt signaling is in APC. In the absence of Wnt ligand, APC binds 
to phosphorylated β-Catenin (Serine 33/39) and forms the destruction complex. β-
Catenin is ubiquitinated and subsequently degraded by the proteasome complex [18] 
(Figure 1.1). Other activating mutations of Wnt pathway can be loss of function of 
Glycogen Synthase Kinase-3β (GSK-3β), which is the kinase responsible for β-Catenin 
phosphorylation at Serine 33/39, constitutive activation of Wnt receptor absent of any 
ligand as well as mutated forms of β-Catenin which are unable to bind APC protein [19].   
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Figure 1.1: Canonical Wnt Signaling.  (a) Absent Ligand, β-catenin remains in complex 
with APC and GSK3β resulting in its phosphorylation and subsequent degradation. (b) 
Ligand bound receptor results in inhibition of GSK3β and β-catenin is then able to 
accumulate and move into nucleus, activating transcription of targeted genes. Figure 
provided by Nature Reviews, Moon 2004.  
5 
 
  
The end result of aberrant Wnt signaling is nuclear accumulation of β-Catenin. 
Cooperating with members of the TCF/LEF family, β-catenin activates a number of 
target genes such as cyclin D1, claudin-1, VEGF and MMP-7, which modulate cell 
proliferation, metastasis and further progression of tumors [8]. Increasing amounts of 
evidence points to a profound effect of inflammation driving further changes in 
morphology, genetic mutations and molecular changes within the tumor and its 
microenvironment as the tumor progresses. 
Inflammatory bowel diseases (IBD) such as Ulcerative colitis and Crohn’s 
Disease are characterized by colitis of the large intestine. Patients with these diseases 
have between a 5 and15 fold increased risk of developing cancer in their lifetimes. The 
tumors arising in these patients are difficult to treat and have a >50% mortality rate [20-
22]. The histopathology of Colitis Associated Cancer (CAC) is very similar to hereditary 
or sporadic CRC, and the same genetic mutations are found within these different 
tumors. A key component in both of these etiologies of CRC is the increased nuclear 
accumulation of β-Catenin. However, the timing of mutations is different: CAC tumors 
display earlier p53 mutations and later Kras mutations, whereas sporadic CRC tumors 
show earlier APC mutations and Kras mutations, with p53 mutations generally arising 
later, as the tumor progresses [22, 23]. This is the case in both mouse models of tumors 
and human tumors. Perhaps inflammation leads to or is a prerequisite of p53 mutation. 
Many groups have shown substantial inflammatory markers increased in CRC. There is 
growing evidence showing robust pro-inflammatory infiltrates as well as increased pro-
inflammatory cytokine levels in CRC without any clinically detectable signs of 
gastrointestinal distress [19]. Moreover, patients with IBD and a family history of CRC 
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are twice as likely to develop cancer, compared to IBD patients without a positive family 
history [24]. Thus there could be a mechanistic overlap and a dependence on 
inflammation, even in hereditary or sporadic CRC. More evidence for inflammation 
being a driver for both sporadic CRC and CAC is the clinical observation that Non-
steroidal Anti-inflammatory Drugs (NSAIDs) such as aspirin confer protection from 
tumor development [25-27].  
Several bodies of evidence have implicated the tumor cells and infiltrating 
immune cells of the colon for the increase in inflammation and the resulting addiction of 
the tumor cells to inflammation. CRC tumors and cell lines show constitutive activation 
of transcription factors that are integral molecules of multiple key inflammatory 
pathways, such as Nuclear Factor-κB (NF-κB) and Signal Transducer and Activator of 
Transcription 3 (STAT3) [28, 29]. β-Catenin alters the anti-tumorigenic function of 
Regulatory-T cells (Tregs) into pro-tumorigenic via increased expression of RORγt 
receptor, which leads to increased inflammatory cytokines [30]. The inflammatory 
environment itself can increase β-catenin nuclear accumulation. For instance, it has 
been shown that TNFα derived from tumor associated macrophages (TAM) in gastric 
cancers can cause the nuclear accumulation of β-catenin in tumor cells [31, 32]. 
Activated macrophages also secrete IL-1β, which stimulates Wnt signaling in CRC cells 
[33]. Thus, the combination of these events (which would occur in both sporadic CRC 
and CAC) lead to an inflammatory microenvironment. This inflammatory environment is 
integral to tumor progression because it allows for further accumulation of mutations, 
promotes maintenance and progression to metastasis in the tumor cells.     
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Nitric Oxide Synthase Modulation in Inflammation  
A hallmark for an inflammatory microenvironment is the increase in reactive 
oxygen/nitrogen species (ROS/RNS) leading to an oxidative state in the cell. One of the 
primary sources of ROS/RNS is Nitric Oxide Synthase (NOS).  There are 3 subtypes of 
NOSs: neuronal (nNOS, NOSI), inducible (iNOS, NOS II) and endothelial (eNOS, NOS 
III) which catalyze the production of nitric oxide (NO) and L-citrulline by the oxidation of 
L-arginine [34].  NOS forms homodimers and uses arginine and molecular oxygen (O2) 
as substrates.  Tetrahydrobiopterin (BH4), NADPH, FAD and FMN are all required as 
cofactors [35].  Both NOS I and NOS III are constitutively expressed in neural cells and 
endothelial cells respectively and are responsible for a low basal level of NO synthesis.  
NOS III is membrane associated and is constitutively expressed in endothelial cells and 
cardiac myocytes and is involved in maintaining vascular tone, platelet aggregation, 
angiogenesis and smooth muscle cell proliferation. The NOS II and III isoforms are 
expressed in a variety of tumor cells [36-38] and for this reason will be the main focus in 
the studies in this dissertation.  NOS I is constitutively expressed in neurons and acts as 
a neurotransmitter in both the central and peripheral nervous system.  In skeletal 
muscle NOS I is responsible for producing large amounts of NO during contraction [39].  
NOS II is found in a variety of cell types including fibroblasts, macrophages, dendritic 
cells, epithelial cells, and some cancer cells.  NOS II plays a role in host immunity and 
upon induction produces 100x more NO than NOS I & III. This burst in NO in an 
inflammatory environment can react with O2- leading to cell toxicity [40].   
Under normal physiological conditions NOS produces NO via the reaction 
mentioned above. The heme moiety of soluble guanylate cyclase (sGC) is the main 
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relevant target of NO at physiological concentrations produced by NOSI and NOSIII. NO 
binding to the heme of sGC leads to the formation of 3,5-cyclic guanylate 
monophosphate (cGMP) from guanosine triphosphate (GTP).  cGMP is the principle 
messenger involved in vasodilation, neurotransmission and platelet aggregation.  NO is 
the primary vasoregulator in mammalian cells and the generation of cGMP results in the 
subsequent activation of cGMP dependent protein kinase (PKG) leading to the 
phosphorylation of vasodilator-stimulated phosphoprotein (VASP) and the inositol 1,4,5-
triphosphate receptor (IP3 receptor) resulting in vasodilation [41]. New evidence shows, 
in tumors cells, activation of PKG to be anti-proliferative and pro-apoptotic [42-44]. Thus 
there is an apparent disconnect between expression of NOSIII and NOSII [37, 38, 45, 
46] and NOS activity in tumor cells and the experimentally observed anti-tumor 
properties of NO. Since NOS is expressed in tumor cells, NO should signal towards  
anti-proliferative and apoptotic pathways. However this is not the case, tumors continue 
to grow and progress. Previous work in our lab, as well as the studies in this thesis seek 
explanations for this phenomenon. 
One explanation is that NOSs in tumor cells do not synthesize NO. Under 
normal, non-inflammatory/non-oxidative states, NOS is said to be coupled with oxidation 
of arginine resulting in the synthesis of citrulline and NO. However under inflammatory 
or oxidative conditions, catalytic cycle of NOS is uncoupled and instead of NO, 
superoxide is formed and NOS is said to be uncoupled. The molecule responsible for 
determining the coupled state is BH4, and the ratio with its oxidized counterpart 
dihydrobiopterin (BH2) [47]. Much of this work was first demonstrated in cardiac tissue 
during myocardial infarctions. In normal non-ischemic tissue NOS is coupled and 
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predominantly produces NO. The BH4:BH2 is high, thus an abundance of BH4. 
However, after an infarct the resulting ischemia and an enhanced oxidative state of the 
tissue cause the oxidation of BH4 to BH2, resulting in a drop of BH4:BH2 ratio. Both 
BH4 and BH2 have equal affinity for NOS, the relative abundance of either molecule 
determines the coupling state of NOS [48-50] (Figure 1.2). Because in either state, both 
BH4 and BH2 are present, there is always a pool of NO producing NOS and O2- 
producing NOS (allowing for the production of ONOO- in varying amounts), the 
predominating pool will differ depending on the oxidative state of BH4. Although much 
of this work was done in cardiovascular research, NOS is uncoupled in other 
inflammatory states such as diabetes [51, 52]. Our lab has shown that NOS is 
uncoupled in a variety of tumor types both in vitro and in vivo. We also showed that 
recoupling NOS with a precursor of BH4, sepiapterin (SP) leads to mitigation of colitis in 
mice [53]. Most recently, we showed that recoupling of NOS in breast carcinomas leads 
to tumor cell killing both in vitro and in vivo [42]. Therefore, even though tumor cells 
express NOS, due to the inflammatory oxidative microenvironment, NOS is uncoupled 
and producing ROS/RNS, which activate proliferative and anti-apoptotic pathways [54-
58].  
Implications of NOS Uncoupling and ROS/RNS Signaling 
The coupling state of NOS determines whether NO or O2-/ONOO- molecules are 
produced. NO generally signals towards homeostatic, non-inflammatory pathways 
dependent and independent of PKG. For example, our lab and others have shown that 
PKG activation leads to an increase in p21 levels, leading to cell cycle inhibition [42-44]. 
ROS/RNS promote cancer cell survival through modulation of receptor tyrosine kinases  
10 
 
  
  
Figure 1.2: NOS Activity is Dependent on BH4:BH2 Ratio. In times of high BH4, NOS is 
coupled and predominantly produces NO, however in situations when BH2 is greater than 
BH4, NOS is uncoupled and produces superoxide and peroxinitrite radicals.   
11 
 
  
(RTK) [59]. RNS are generated by a reaction of ROS with NO. Peroxynitrite (ONOO-), 
produced from the reaction of NO with O2-, is a powerful oxidizer which can react with 
amino acids, metal containing compounds, nucleic acids and plays a major role in 
cellular injury and cell death at high levels of ONOO-. However at lower concentrations 
(such as during inflammatory states), ONOO- nitrates tyrosines on specific protein and 
leads to activation of cytoprotective mechanisms such as NFκB and Akt [56, 60-62].  
Generation of ROS/RNS leads to altered cellular function through protein Tyr 
nitration and Cysteine (Cys) S-nitrosylation or S-oxidation.  Tyrosine nitration involves 
the incorporation of a nitro group (-NO2) to the ring structure of tyrosine residues 
resulting in the formation of 3-nitrotyrosine. Biologically relevant protein Tyr nitration has 
been proposed to occur through several mechanisms: the generation of NO2 radicals, 
reaction of NO with tyrosyl radicals, and through generation of ONOO- [63].  Our work 
and others have validated the role of Tyr nitration and Cys S-nitrosylation as relevant 
cellular signaling mechanisms (Figure 1.3) [56, 61, 64-66].  Both processes are 
selective and reversible and these modifications can cause activation or inhibition of 
certain cellular pathways depending on the target.  For example, our lab has 
demonstrated that nitration of IB is critical for the IR-induced activation of the pro-
inflammatory transcription factor, NF-B. Our lab has also shown that p53 can be 
nitrated and become activated due to low doses of NO donors or IR. Lastly, our lab has 
shown that physiological levels of NO/RNS lead to downregulation of BRCA1 leading to 
DNA damage repair via non-homologous end joining, rather than homologous end 
joining [67]. This may be a mechanistic explanation of how an increase in ROS/RNS 
can lead to an increase in genetic mutations.  
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Figure 1.3: NOS Signaling is Dependent on Coupling State. Coupled NOS produces NO and 
signals towards anti-inflammatory/pro-apoptotic effector molecules such as PKG. However 
uncoupled NOS produces oxidative signaling, which leads to more proliferative and anti-
apoptotic signals.  
13 
 
  
Akt, is an oncogenic protein that is activated in a variety of tumors. It is an 
integral component for activating pathways necessary for tumor growth, anti-apoptosis 
and metastasis. Recently, one mechanism of Akt regulation is via Cys S-nitrosylation. 
Cys. S-nitrosylation occurs through direct interaction of NO with the thiol group of 
cysteines resulting in the formation of a nitrosothiol (S-N=O) [68]. Numajiri et al showed 
that in areas of ischemia (with an increased amount of ROS/RNS and low NO) 
phosphatase with sequence homology to tensin (PTEN, phosphatase which inhibits PI-
3K) was S-nitrosylated and inhibited, leading to the activation of Akt. However, in areas 
with higher NO, Akt was S- nitrosylated and inactivated [69]. The S-nitrosylation of Akt 
was shown to be at a specific cysteine, Cys-224 [68]. Thus a possible way tumor cells 
activate Akt is using uncoupled NOS (low levels of NO) to preferentially inhibit PTEN 
leading to increased Akt activity.   
Many labs, including ours have shown that protein tyrosine phosphatases (PTPs) 
are also regulated by this S-nitrosylation mechanism. SHP-1 and SHP-2 have been 
demonstrated by our laboratory and by others to be regulated by S-NO [70-72]. The end 
result of this is to inhibit PTPs and activate receptor tyrosine kinases, such as Epidermal 
Growth Factor Receptor (EGFR) and Insulin Receptor, allowing for uncontrolled growth. 
S-nitrosylation of the active site cysteine of Caspases has been shown to inhibit 
apoptosis in many cell types such as hepatocytes, endothelial cells, and tumor cells [73-
75].  The activation of proliferative and anti-apoptotic pathways is dependent on an 
inflammatory oxidative state which is produced due to the generation of ROS/RNS in 
the tumor cells and infiltrating immune cells. The end result is a deadly cycle of 
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inflammation and propagation of tumor cells leading to further inflammation and more 
malignant tumor cells. 
Scope of Dissertation 
The studies in this dissertation seek to determine what role NOS activity may have in 
progression of CRC and therapeutic potential of modulating the coupling state of tumor 
NOS. Earlier work in our lab showed that recoupling breast cancer cells with SP led to a 
decrease in β-catenin. I hypothesize that SP may have similar tumoricidal effects in 
colorectal cancer cells due to their dependency on Wnt signaling to promote 
tumorigenesis.  
Our lab has shown that NOS is uncoupled in a variety of tumor cells both in vitro and in 
vivo. Using a precursor of BH4, sepiapterin (SP), we can recouple NOS and raise the 
BH4/BH2 ratio and lower superoxide production in tumor cells. SP feeds into the 
salvage pathway of biopterin metabolism and is converted via Sepiapterin Reductase 
(SR) and Dihydrofolate Reductase (DHFR) to BH4. We also showed that SP was 
tumoricidal in MDA-MB231 and MCF-7 cells, as well in vivo in xenografts of these cell 
lines as well as MMTV-Neu mice with spontaneous tumors. The recoupling of NOS led 
to activation of PKG and subsequent down regulation of β-catenin and activation of p21 
(cell cycle inhibitor) as well as a decrease in Cyclin D1. The end result was decreased 
proliferation in tumor cells. We also examined the effects of sepiapterin in a murine 
model of CAC. Colitis and tumor formation are induced by the carcinogen 
Azoxymethane, and 3 one week cycles of dextran sodium sulfate (DSS) followed by 
normal drinking water. During the DSS cycles mice develop colitis which is apparent as 
weight loss, stool consistency and presence of blood in stool (collectively called Disease 
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Activity Index DAI). Mice develop tumors during the 10 week treatment course. SP was 
given prophylactically to a group of animals from the first DSS cycle and continued for 
12 weeks. SP treated animals had a significantly less DAI as well as a diminished tumor 
burden.  
In this thesis, I seek to determine the mechanism of decrease in β-catenin expression 
and to determine if SP can be used as a therapy (after tumors have developed) rather 
than prophylactically. Lastly, I will seek to determine mechanistic explanations of how 
tumor colorectal tumor cells maintain a decreased BH4:BH2 ratio. Studies in chapter 2 
will show the effects of SP in vitro. The studies in chapter 3 will demonstrate that SP 
can be used therapeutically to have tumoricidal effects in murine CAC in vivo as well. 
Additionally, studies in chapter 3 will also seek to elucidate a mechanistic explanation 
for the decrease in BH4/BH2 ratio. 
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Chapter 2: 
 Recoupling of NOS in vitro decreases proliferation of colorectal tumor cells 
BH4 is a necessary cofactor for the production of NO from NOS.  Evidence has 
shown that NOS generates O2- under certain pathophysiological conditions. Both BH4 
and its oxidized version, BH2 have equal affinity for NOS, thus their relative levels are 
important in regulating the balance of O2- and NO produced by NOS. In conditions 
where BH4 levels are low and high BH2, electron transfer in the active site of the 
enzyme becomes uncoupled from L-arginine oxidation resulting in the production of O2- 
instead of NO [47]. The uncoupled enzyme therefore becomes a generator of ONOO-, 
which is produced rapidly by the reaction of O2- with NO produced in the same area.  
The reaction of NO with O2- is six times faster than the reaction of O2- with SOD so 
ONOO- formation is favored [60].  Figure 1.3 illustrates some of the cellular 
consequences of an uncoupled NOS.  With uncoupling cell signaling shifts from sGC 
activation and S-nitrosylation towards reduced cGMP/PKG activity and ONOO- and 
protein nitration.  
Earlier studies in our lab showed that in a variety of tumor cells and tumor 
tissues, BH4:BH2 ratios are lower than normal non-tumor tissue counterparts. As seen  
in Table 2.1 we measured BH4:BH2 ratios in a variety of in vitro cell lines. For example, 
in HT29 colon tumor cell line, we found its BH4:BH2 ratio was lower than normal colonic 
tissue. We next sought to determine if SP is able to raise BH4:BH2 ratios in both cells 
and animals. Exogenous SP was able to raise BH4:BH2 ratios both in vitro and in vivo. 
Another interesting finding of our study was that when we compared healthy colonic 
tissue with tumor colonic tissue from human patient samples, there was about a 2 fold  
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Figure 1.4: Summary of BH4:BH2 Ratios in Different Tissues. BH4:BH2 Ratios were measured in 
vitro and in vivo tissues using HPLC. Ratios were measured in normal/non-tumor tissue, in 
untreated cultures as well as with SP treated cells and tumor bearing animals. Values are given ± 
SEM.  
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decrease in BH4:BH2 ratios in the tumors of these patients. Furthermore, we saw a 
decrease in O2- formation and decrease in nitro-tyrosine staining (a surrogate marker for 
ROS/RNS). Collectively, these results provide evidence that BH4:BH2 ratio is low in 
tumor tissue, NOS is uncoupled and ROS/RNS are elevated; however we can 
exogenously raise BH4:BH2 ratio by treating cells and animals with SP.  
ROS/RNS at higher levels signal towards proliferative pathways. Our lab has 
shown that after IR and treatment with peroxynitrite, IκBα is nitrated which leads to 
active components of NF-κB, p65 and p50 translocation into the nucleus which lead to 
activation of multiple proliferative and inflammatory pathways. Many groups 
demonstrate that AKT is activated after oxidative stress as well as many other pro-
survival and pro-inflammatory pathways [57]. The end result of this oxidative signaling is 
to help the cell survive an insult, or in the case of tumor cells to continue to grow, 
accumulate mutations and progress to metastatic state. By raising BH4:BH2 ratio, we 
can mitigate these pathways. We have shown decreased p65/p50, STAT3 and β-
catenin in the nucleus after SP treatment in breast cancer cell lines. Most importantly, 
SP was able to decrease colony formation in breast cancer cell lines in vitro and ex 
vivo, thus the increase in BH4:BH2 is tumoricidal to breast cancer cell lines. In order to 
determine if SP has applications in multiple tumor types, we want determine if SP has 
similar tumoricidal effects in colorectal cancer cell lines. If, indeed it does, we also seek 
to determine the mechanism by which SP is acting in these colorectal cancer cell lines. 
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Materials and Methods: 
A. Chemicals and Reagents 
Pterin (#11.903), L-Sepiapterin (#11.225), Biopterin (#11.203), 7,8 Dihydro-L-
Biopterin (#11.206) , and (6R)-5,6,7,8-Tetrahydro-L-biopterin dihydrochloride 
(#11.212) were from Schircks Laboratories (Jona, Switzerland).  Sodium 
Deoxycholate (D6750), Sodium Thiosulfate (S7026), Silver Nitrate (S1179), 
Potassium Carbonate (209619), 40% Formaldehyde (F8775), Ascorbic Acid 
(A5960), Potassium Iodide (P-4286), Nώ –Nitro-L-arginine (N5501), SB 216763 
(S3442), S-Nitrosoglutathione (N4148) and Iodine (20,777-2) were from Sigma 
Aldrich.  Hydrochloric Acid (A144-212), Sodium Hydroxide (SS255-1), HPLC 
grade Methanol (A452-4), HPLC grade Water (W5-4), DMSO (D128), HPLC 
grade Acetonitrile (26827-0040), Trifluoroacetic Acid and Perchloric Acid (A229) 
were purchased from Fisher Scientific.  Peroxynitrite (81565), Nitrotyrosine 
Affinity Sorbent (389549) and cGMP EIA kit (581021) were purchased from 
Cayman Chemical.  PBS (10010-023) RPMI 1640 (11875-093), Trypsin EDTA 
(15400-054), Penicillin Streptomycin (15240-062), Lipofectamine (50470) and 
Plus Reagent (10964-021) for transfection were purchased from Invitrogen.  
Matrigel (356234) was purchased from BD Biosciences and dihydroethidium 
(D11347) was from Molecular Probes. For animal studies involving treatment 
with SP, stock solutions of 0.8mg/ml in H2O were frozen at -20˚C.  When ready to 
use they were thawed and 1ml was diluted to 40ml in animal drinking H2O.  For 
tissue culture studies involving SP we used a 0.25% DMSO plus tissue culture 
medium as the solvent to make a 1mM stock solution which could then be diluted 
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as necessary (A .005% DMSO solution was used as vehicle/control treatment 
group).  These solutions were made fresh each time cells were to be treated. 
The following primary antibodies were used:  Actin (sc-1616) were from Santa 
Cruz Biotechnology (Dallas, TX).  anti-cyclin D1 (2978), anti-JNK1/SAPK (4668), 
anti-pGSK3β (9323) and anti-Stat3 (9131) were from Cell Signaling Technology 
(Danvers, MA). Anti-β-Catenin (610153) was from BD Transduction Laboratories 
(Franklin Lakes, NJ).  The secondary antibodies used were conjugated with near 
infrared fluorophores designed for use with the Li-Cor Odyssey Infrared Imager:  
anti-rabbit 800 (611-132-003), and anti-goat 700 (605-730-002), were from 
Rockland Immunochemical (Gilbertsville, PA).   
B. Cell Culture 
HCT116 cells were purchased from ATCC (Manassas, VA) and HT29 and 
CACO2 were generously provided to us by Dr. Andrei Ivanov (VCU Department 
of Pharmacology and Toxicology).  All cell lines were grown as monolayers in 
McCoys 5A Media (Life Technologies) supplemented with 10% FBS and 
50units/ml penicillin and streptomycin.  Cells were incubated at 37˚C in 5% CO2.  
Cells were passaged as necessary. 
C. BH4 and BH2 measurements 
HCT116 and HT29 cells were plated at a density of 2x106 cells/100mm dish and 
were allowed to adhere overnight.   The next day cells would receive the 
indicated treatment and would then be placed back in the incubator for the 
duration of treatment.  When the cells were ready to be harvested the dishes 
were washed in ice cold 1x PBS three times.  After the final wash all PBS was 
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aspirated off and the cells were then lysed in 1ml of ice cold 0.1N HCl and placed 
in a 1.5ml microcentrifuge tube.  The samples would sit on ice for 20min and then 
] centrifuged for 20min at 13,200 RPM.  The supernatants were divided into 
aliquots and placed either into a -80˚C freezer or analyzed immediately for BH4 
and BH2 content. The pellets were dissolved in Laemmili sample buffer for 
protein analysis by Western blot. To analyze biopterin levels in tumors or other 
mouse tissues animals were anesthesized with isofluorane and euthanized by 
cervical dislocation.  Once the animal was sacrificed we harvested the desired 
tissue and snap froze it in liquid nitrogen.  The tissue was either placed in the -
80˚C freezer or immediately homogenized in 10 volumes of 0.1N HCl with a 
pestle and mortar kept on ice.  The resulting tissue homogenate was centrifuged 
for 20min at 13,200 rpm and the supernatant was be stored in aliquots at -80˚C.  
 
The protocol for HPLC analysis was adapted from Woolfe et al (1983).  
Three solutions were needed in order to perform the acid/alkaline oxidation:  
2%I2/3%KI in 0.1N HCl, 2%I2/3%KI in 0.2N NaOH, and 2.5% Ascorbate in 0.4N 
perchloric acid.  100µl of sample was incubated with 62.5µl of the HCl solution in 
one tube while another 100µl of sample was incubated with the NaOH solution 
for 1h at room temperature in the dark.  After 1h, 0.5 vol of the ascorbate solution 
was added to each tube and the samples centrifuged at 12,000 RPM for 10min.  
50µl of the resulting supernatant from each sample was separated by HPLC on a 
Whatman RTF partisphere column using 5% methanol as the mobile phase at a 
flow rate of 1.0ml/min and fluorescent detection at 350/450nm. To determine the 
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BH4:BH2 ratio I compared the acidic and alkaline chromatograms for each 
sample.  Under acidic conditions both BH4 and BH2 were converted to biopterin 
and eluted in one peak, while under alkaline conditions BH4 was converted to 
pterin and now eluted in a different peak.  Comparing the areas under the curve I 
was then able to obtain the BH4:BH2 ratio.   
D. Cell Viability Assays (WST) 
WST-1:  Cells were washed, trypsinized and counted in a hemocytometer.  This 
assay is performed in a 12 well plate and samples are plated in triplicate.  50 
x103 cells/well in 2mL of medium were plated and allowed to incubate overnight 
to adhere. To determine cell viability 4µl of WST-1 reagent was added to the well 
and allowed to incubate for 3 hours before.  The formazan that is formed by 
metabolically active cells is then quantified by spectrophotometer at 420-480nm.  
For our experiments involving SP treated cells, if the treatment was longer than 
24 hours, fresh media with appropriate concentration of SP was put on the cells 
every day until the end of the treatment period. Appropriate concentrations of SP 
plus Media was used as the blank during plate reading. 
E. Clonogenic Assay:   
Cells were trypsinized and plated in 10cm dishes.  200 cells were plated in the 
control dishes while 500 cells were plated in the treatment groups.  Dishes were 
treated with varying concentrations of SP 16 hours after plating.  When the 
colony size reached 50 cells, cells were fixed in -20˚C methanol, stained with 
0.5% crystal violet and counted. 
F. Western Blot Analysis 
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Protein was extracted from ~80% confluent cell layer in (150uL/6cm dish) in 
RIPA lysis buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, 5 mM EDTA) and processed under reducing 
conditions. Alternatively tissue culture cells were harvested in 1X Laemmli 
sample buffer.  Proteins were resolved by SDS-polyacrylamide gel 
electrophoresis and transferred to nitro-cellulose membranes. Membranes were 
incubated with the primary antibody of interest overnight at 4°C. Blots were 
developed using IR 700 or IR 800 conjugated secondary antibodies (Rockland 
Immunochemicals, Gilbertsville, PA) diluted 1:10,000 and imaged/analyzed using 
the Odyssey Licor system. 
G.  shRNA Lentiviral Transduction 
GSK3β shRNA Lentiviral Particles-A (sc-270460-V) and Control shRNA Lentiviral 
Particles-A (sc-10808) were purchased from Santa Cruz Biotechnology (Dallas, 
TX). In a 12 well plate, HCT-116 cells were plated to achieve ~50% confluence 
the following (infection) day in complete McCoy’s Media (10% FBS). 1mL/well of 
complete media with 5ug/mL of Polybrene (sc-134220) and 20uL of appropriate 
Lentiviral Particle was prepared as infection media. Complete growth media was 
replaced with infection media and incubated overnight for 12 hours. Media was 
changed to fresh complete growth media and incubated overnight. To select 
stable clones, cells were split 1:3 from original 12-well plates and grown for 48 
hours in 10cm dishes. shRNA expressing clones were selected by treating 
dishes with 10ug/mL of Puromycin dihydrochloride (sc-108071) in complete 
growth media. Fresh puromycin was replaced every 3-4 days. After 2 weeks of 
growth under puromycin selection, cells were split 1:50 into multiple dishes. 
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Single colonies were picked under sterile conditions and grown to confluence 
under puromycin selection. These clones were then analyzed via western blot 
analysis for GSK3β expression.  
H. TCF/LET Luciferase Reporter Assay 
HCT-116 cells were plated at a density of 1x105 cells/60mm dish and were 
allowed to incubate for 24 hours to adhere.  Since cells were to be transfected 
with the TCF/LEF construct 24 hours before harvesting, I  had to treat cells with 
SP accordingly. All cells were placed in fresh 10% medium after transfection.  
The cells were washed in ice cold PBS and harvested in the lysis buffer provided 
in the kit.  I followed the protocol in the kit exactly 
I. AKT Activity Assay  
The Akt activity assay kit was purchased from Cell Signaling Technology (#9840) 
and their protocol followed. Briefly, cells were lysed in provided buffer and Akt 
was immunoprecipitated overnight using AKT Ser473 antibody-immobilized 
beads. After washing the beads (3X), the kinase assay was performed with 
GSK3β substrate and 10mM ATP at 30ºC. After termination, the samples are 
analyzed via western blot, blotting for phosphorylated GSK3β. Western blots 
were quantified by densitometry and the average  for 3 experiments was 
normalized to control.  
J. Biotin Switch Assay: Analysis of S-nitrosylated Proteins 
 
This method was used to determine Cys S-nitrosylation.  For total cellular S-
nitrosylation, cells were grown to 80% confluent and then harvested.  For 
analysis of a specific protein it was typically overexpressed. HCT-116 cells, 
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1.2x106 cells were plated and allowed to adhere overnight. The resulting cell 
lysate was centrifuged for 5 min and the supernatant was mixed with blocking 
buffer (250mM Hepes pH 7.7, 1mM EDTA, 0.1mM neocuproine, 2.5% SDS, 
20mM MMTS ) to block all free sulfhydryls.  The sample was then mixed with 
acetone to precipitate the proteins to remove MMTS.  The preceding steps are 
done under conditions of low light as to not create additional reactive Cys from 
exposure to UV.  The pellet is resuspended in Hens buffer (25mM Hepes 7.7, 0.1 
mM EDTA, 10µM neocuproine, 1% SDS) to which is added biotin-HPDP and 
ascorbate to a final concentration of 1mM.  Samples incubate for 1 hour at room 
temperature.  Proteins are again precipitated with acetone to remove excess 
biotin.  Proteins are resuspended in neutralization buffer (20mM Hepes, 100 mM 
NaCl, 1mM EDTA, 0.5% Triton X-100)  and the biotin labeled proteins are 
purified on streptavidin-agarose beads overnight, washed the following day with 
wash buffer (neutralization buffer with 600mM NaCl) and then eluted in sample 
buffer containing β-mercaptoethanol.  The samples were then resolved by SDS-
Page.  Western blots are probed with streptavidin for total s-nitrosylation or with 
antibodies for specific proteins.   
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Results: 
Sepiapterin Raises BH4:BH2 ratio in colorectal cancer cells and decreases 
proliferation 
 Previous studies in the lab had shown that many tumor cell lines have decreased 
BH4:BH2 ratios compared with their normal tissue counterparts. In order to determine if 
SP is having any effects on our colorectal cell lines, we first needed to determine if SP 
was able to raise BH4:BH2 ratios significantly in CRC cell lines. HCT-116 and HT29 
cells were treated with 20µM SP for 24 hours and analyzed for BH4:BH2 ratio via HPLC 
(Table 2.2). SP treatment increased the BH4:BH2 ratio by more than two fold in HT29 
cells and about a 5 fold increase in the ratio in HCT-116 cells compared to baseline. 
Next the effects on proliferation of HCT-116 cells when treated with SP were 
determined via WST assay. Treatment by SP of HCT-116 was able to decrease cell 
growth, as measured by WST absorbance during a 5 day treatment course (Figure 2.1). 
Colony formation assays were used to determine if SP has direct cell killing effects. 
Increasing concentrations of SP led to increased cell death. A 30-40% cell killing effect 
at 20µM in both HCT-116 and HT29 cell lines was seen, which is the concentration 
used in further experiments (Figure 2.2). These data suggested that SP did have a 
cytotoxic effect on CRC cell lines and next we sought to determine the mechanism of 
action of SP.  
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Table 2.2: BH4:BH2 Ratios in Colorectal Cancer cells  
BH4:BH2 Ratios were measured in vitro colorectal cancer cell lines using HPLC. Ratios were 
measured in untreated cultures as well as with SP treated cells. In both types of cell lines, SP 
was able to raise BH4:BH2 ratio. Values are given ± STD.  
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Figure 2.1 WST Cell Proliferation Assay. HCT-116 Cells were treated with SP 
for noted number of days and after treatment with WST, absorbance was measured to 
estimate cell proliferation. SP was able to decrease cell proliferation after 3 days of 
treatment. Absorbance was normalized to untreated cells.   
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Figure 2.2 In Vitro Clonogenic Assays. (A)HCT-116 Cells and (B) HT29 Cells were treated with 
SP at the concentrations noted for 24 hours. Cells were then plated in triplicate at counts of 
100, 500 and 1000 cells/dish and allowed to grow to visible colonies. Colonies were 
normalized to untreated cells and assessed for statistical significance using the student’s t-
test. *p <0.05 as compared to untreated cells.     
* 
* 
* 
* 
* 
* 
* * * 
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Sepiapterin decreases expression of β-catenin by activating GSK-3β in colorectal 
cancer cell lines  
Earlier studies in the lab demonstrated that β-catenin levels were downregulated 
in breast carcinoma lines. HCT-116, HT29 and CaCo2 CRC cell lines were used to 
determine if SP had any effect on β-catenin expression. In all three cells lines we tested, 
β-catenin levels were decreased after 4 and 5 day treatment course (Figure 2.3). To 
confirm that SP was able to decrease transcription activity of β-catenin a LET/TCF 
luciferase promoter activity assay was employed. In HCT-116 cells, SP was able to 
significantly decrease LET/TCF driven luciferase expression after 3 and 5 days of 
treatment (Figure 2.4). The next question to answer was to determine what was causing 
decreased β-catenin levels. AKT is potent activator of Wnt signaling. AKT 
phosphorylates GSK3β at Serine 9 causing it to become inactive. GSK3β is then unable 
to phosphorylate β-catenin, leaving β-catenin able to translocate to the nucleus and 
bind its target DNA. AKT is also activated during times of oxidative stress. Since SP 
increases BH4:BH2 ratio thereby decreasing oxidative stress, AKT activation should 
also be decreased. Phosphorylation of Ser473 on AKT (marker for its activation) was 
measured via western blot and in our colorectal cell lines there was decreased 
phosphorylation of Ser473 (Figure 2.5). Next, an in vitro kinase activity assay was used 
to determine if indeed AKT activity was decreased after SP treatment. As seen in Figure 
2.6A, AKT activity was significantly decreased after SP treatment. GSNO (an NO donor) 
was used as a positive control because we suspected AKT was S-nitrosylated due to 
the increase in NO formation from NOS. Previous work in other labs has shown that NO 
donors can S-nitrosylate AKT rendering it inactive. Using the biotin switch method, SP 
was able to S-nitrosylate AKT and in conjunction with the western blot and activity  
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Figure 2.3 Western Blot Analysis of β-catenin after SP Treatment. (A)HCT-116,(B) HT29 
and (C) CaCo2 cells were treated with SP at 20 µM for 1-5 days. Cells were then lysed and 
analyzed via western blots for protein analysis. Representative blots are shown from 
experiments done at least 3 times in each cell line.  
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Figure 2.4 LET/TCF Luciferase Promotor Activity Assay. HCT-116 cells were treated with 20µM 
SP for 3 and 5 days continuously. 24 hours before harvesting cells were transfected with a 
plasmid encoding luciferase driven by nuclear β-catenin binding to LET/TCF promoter site. 
Luciferase activity was measured 3 and 5 days post SP treatment. Results are quantified from 2 
separate experiments done in triplicate. Results are normalized to untreated cells and reported 
as ± SEM. Student’s t-test was used to assess for statistical significance.  
33 
 
  
 
  
Figure 2.5 Western Blot Analysis of AKT and GSK3β after SP Treatment. (A)HCT-116, (B) HT29 
cells were treated with SP at 20 µM for 1-5 days. Cells were then lysed and analyzed via 
western blots for protein analysis. Representative blots are shown from experiments done at 
least 3 times in each cell line.  
A. 
B. 
A. 
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Figure 2.6 AKT Activity Assay and S-Nitrosylation after SP Treatment. (A) AKT activity 
assay, HCT-116 were treated with 20µM SP and/or 100nM L-N
G
-Nitroarginine (L-NNA, 
NOS inhibitor) for specified days and 1mM GSNO (added directly to cell lysate, as 
positive control). AKT in vitro kinase activity was measured, bar graph is average of 
activity measured in 3 assays performed with a representative blot from one 
experiment.*p< 0.05, using student’s T-test. (B) Biotin Switch Assay in HCT-116 cells 
with 20µM SP treatment after 1 or 3 days and GSNO (as positive control), 
representative blot from 2 separate and independent experiments is shown.  
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Figure 2.7 Western Blot Analysis of downstream targets of GSK3β after SP Treatment. (A)HCT-
116 cells were treated with 20µM SP for specified days and analyzed for phosphorylation of β-
catenin at Ser 33/37 (A) and cdc25A (B) which is another target of GSK3-β regulation. 
Representative blots are shown from experiments done at least 3 times in HCT-116 cells. 
A. 
B. 
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assays, cause it to lose its activity (Figure 2.6B). Due to the decrease in AKT activity, 
we expected to see less Ser9 phosphorylation of GSK3β, which was the case in both 
HT29 and HCT-116 cells (Figure 2.5). Lastly, we saw increased phosphorylation of β-
catenin at Ser33/37 (GSK3β’s phosphorylation site) which marks β-catenin for 
degradation in HCT116 cells (Figure 2.7A). To confirm increased GSK3β activity, we 
saw decreased levels of CDC25A, an important activator of the cell cycle which is also 
phosphorylated by GSK3β and subsequently degraded (Figure 2.7B). Thus, in CRC 
cells, SP leads to decreased activation of AKT and corresponding increased activation 
of GSK3β, causing decreased β-catenin and CDC25A levels leading to decreased 
proliferation and cell death. This mechanism seems to be dependent on GSK3β. 
Pharmacological inhibition of GSK3β or genetic knockdown leads to an 
abrogation of SP’s effects.  
  GSK3β in colorectal cancer cells is integral in regulating Wnt signaling and a 
variety of anti-proliferative and apoptotic pathways. Furthermore, our previous work 
shows SP is activating GSK3β to downregulate β-catenin levels in HCT-116 and other 
colorectal cancer cell lines. Thus to confirm GSK3β’s role in SP’s anti-proliferative 
effects in these cells, we decided to treat HCT-116 cells with SB 216763 (Sigma), a 
specific inhibitor of GSK3β. Treatment with SB 216763 and SP blocked the loss of β-
catenin when cells were concurrently treated with SP (Figure 2.8). To confirm the 
effects of pharmacologic inhibition of GSK3β, we decided to clone stably transfected 
cells expressing shRNA for GSK3β knockdown. Genetic knockdown is confirmed in 
Figure 2.9. We next performed experiments to determine effects of SP in scramble and 
GSK3β knockdown cells. Our results show that with genetic knockdown of GSK3β, we 
lose the effects of SP on β-catenin. Using shGSK3β cells we also examined the effect  
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Figure 2.8 Western Blot Analysis of SP effects with GSK3β Pharmacologic Inhibition. HCT-116 cells were 
treated with 20µM SP and/or 10µM of SB216763 (SB) for specified days and analyzed for β-catenin expression. 
CON = untreated cells. Representative blots are shown from experiments done 3 times in HCT-116 cells. 
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Figure 2.9 Western Blot Analysis GSK3β Knockdown in HCT-116 Cells after SP Treatment. 
(A) HCT-116 cells were transfected with lentivirus containing shGSK3β or scramble shRNA. 
Single colonies were picked, passaged and analyzed for GSK3β expression. 3 different clones 
for GSK3β knockdown and 2 clones for shSCR were used in subsequent studies. (B) shCONC 
or (C) shGSK3β.I were treated with  20µM SP for specified days and analyzed for SP’s effects 
after GSK3β knockdown. Representative blots are shown from experiments done at least 3 
times in transfected HCT-116 cells. 
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Figure 2.10 LET/TCF Luciferase Promotor Activity Assay with GSK3β Knockdown HCT-116 Cells. HCT-
116 cells transfected with GSK3β or scramble shRNA were treated with 20µM SP for 3 and 5 days 
continuously. 24 hours before harvesting cells were transfected with a plasmid encoding luciferase 
driven by nuclear β-catenin binding to LET/TCF promoter site. Luciferase activity was measured 3 and 
5 days post SP treatment. Results are normalized to untreated cells and reported as ± SEM. Student’s 
t-test was used to assess for statistical significance between untreated shCON 5D, versus shGSK3.G 
and shGSK3.I at 5 days. *p ≤ 0.05 
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Figure 2.11 In Vitro Clonogenic Assays with GSK3β Knockdown HCT-116 Cells. HCT-116 cells 
transfected with GSK3β or scramble shRNA were treated with 20 µM SP for 24 hours. Cells were then 
plated in triplicate at counts of 100, 500 and 1000 cells/dish and allowed to grow to visible colonies. 
Colonies were normalized to untreated cells and assessed for statistical significance using the 
student’s t-test between shCON.C and shCON.D and shGSK3.I and shGSK3.G after SP treatment *p 
<0.05.     
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of SP on LET/TCF luciferase activation (Figure 2.10) as well as colony formation in 
GSK3β knockdown HCT-116 cells (Figure 2.11). In both cases, knockdown of GSK3β 
caused mitigation of SP’s effect on colony formation as well as abrogated the loss 
luciferase expression in our assay. However, we did not see a complete loss of SP’s 
effect on colony formation in these cells, suggesting SP has other mechanism(s) which 
can decrease cell proliferation. 
Discussion: 
 The objective of the experiments in this chapter were to determine what effects 
SP had on colorectal tumor cells. To this end, the studies showed that SP was able to 
increase the BH4:BH2 ratio in CRC cells. SP also led to a decrease in cell proliferation 
of HCT-116 cells, as well as decrease the colony formation ability in HCT-116 and HT29 
cells. Next we sought to determine the mechanism of action of SP in these cell lines. SP 
decreased the protein levels of β-catenin, and as a consequence----- (via luciferase 
activity assay) in HCT-116 cells. We also examined regulators of Wnt signaling, namely 
Akt and GSK3β. Akt negatively regulates GSK3β and leads to accumulation of β-
catenin. When we treated our CRC cells with SP, we saw less activation of Akt and 
increased GSK3β activation. GSK3β led to phosphorylation of β-catenin and its 
downregulation. SP also led to the S-nitrosylation of Akt, a modification dependent on 
an increase in NO.  Inhibition and genetic knockdown of GSK3β led to abrogation of 
SP’s effects of β-catenin levels, LET/TCF activation as well as a mitigation of cell death.  
 Previous work in our lab had shown that SP’s effects in breast cancer cells were 
mainly through activation of Protein Kinase G. Although our colorectal cells express 
PKG, none of the targets of PKG showed any changes, such as p21, p27 and cyclin D. 
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A possible explanation for why I did not see PKG activation in CRC cells was due to the 
high levels of cGMP phosphodiesterases (PDEs) in colorectal tumors [76-78]. Thus 
even though we elevated NO levels, cGMP levels would not rise due to PDE activity. 
Future studies can combine SP with PDE inhibitors to increase SP’s tumoricidal effects. 
Although these studies focused on AKT and GSK3β, we cannot rule out other anti-
proliferative/pro-apoptotic pathways as well, due to the observation that there was cell 
death in HCT-116 cells even with GSK3β knockdown (Figure 2.11). In fact, we have 
seen in our CRC cells, decrease of STAT3 Tyr705 phosphorylation after SP treatment. 
Current studies are underway to examine SP’s effects on STAT3. Earlier work in our lab 
has shown that STAT3 activation, as well as NFκB, is decreased with SP treatment as 
well. We believe that by increasing the BH4:BH2 ratio and re-coupling NOS, SP 
decreases the oxidative stress in cancer cells. Tumor cells rely on an oxidative 
environment to activate proliferative pathways which help incur mutations, provide a 
selective growth advantage and eventually lead to more invasiveness and metastasis.  
 S-nitrosylation of AKT has been shown to be an important regulator of AKT 
activity [69]. Numajiri et al showed that in areas of low NO, PTEN is preferentially S-
nitrosylation leading to an increase in AKT activity, however when the NO concentration 
is high, AKT is S-nitrosylated at Cys-224 and inhibited. This mechanism may be an 
important sensor for oxidative stress and fits with NOS uncoupling during ischemia and 
inflammation. During ischemia, in order to survive, cells must activate pro-proliferative 
mechanisms such as AKT-dependent pathways. A common denominator in 
inflammatory states such as ischemia (and the tumor microenvironment) is a decrease 
in BH4:BH2 ratio. The drop in BH4, leads to an uncoupled NOS and a decrease in the 
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relative NO concentration. This leads to an inhibition of PTEN, activation of AKT and 
downstream signaling leading to proliferation and survival. Tumor cells may use this 
mechanism to activate AKT to continue proliferation and avoid apoptosis. By treating 
cells with SP, we are able to recouple NOS and increase NO production and inhibit AKT 
activity. A future experiment to corroborate this finding will be to see what happens to 
levels PTEN S-nitrosylation with SP treatment. We would suspect less S-nitrosylation, 
although it is unclear how the concentration difference effects which protein is S-
nitrosylated. Perhaps PTEN has a more readily accessible cysteine as compared to 
AKT. Another possible explanation could be the subcellular location of NOS relative to 
the location of AKT and PTEN, thus affecting the relative amount S-nitrosylated 
proteins. Lastly, our lab and others have realized a potential limitation of the biotin 
switch assay. This method detects all oxidized cysteines, not just S-nitrosylated (which 
is NO mediated) but also sulfenic and sulfonic acid oxidized cysteine modifications 
which are irreversible ONOO- /O2- dependent [79, 80]. Thus in the ischemic state, which 
is rich in ROS/RNS, PTEN may actually be modified to an oxidized cysteine, whereas in 
states where NO concentration is higher (with lower ROS/RNS levels) AKT is 
preferentially S-nitrosylated. The end result will still be similar, PTEN will be inhibited 
due to its oxidized cysteine in ischemic state, allowing AKT activation.  In our biotin 
switch assays, we used ascorbate which leads to selective immunoprecipitation of s-
nitrosylated proteins and avoids sulfonic/sulfenic acid derivatives.    
 As mentioned earlier in the introduction, there are two different schools of 
thought on NOS and NO signaling in cancer cells. Many groups have shown, including 
our lab, that inhibition of NOS leads to decreased tumor growth and proliferation [42, 
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81-85]. These studies have also shown that NO donors can decrease tumor 
proliferation and increase apoptosis. Other groups have shown that NOS and treating 
cells with NO donors leads to tumor growth [38, 45, 86-90] . We believe one of the main 
reasons for these conflicting reports is the coupling state of NOS. We have shown that 
in a variety of tumor cell lines both in vitro and in vivo, NOS is uncoupled. An uncoupled 
NOS produces ROS/RNS preferentially. With this in mind, it becomes easier to interpret 
the conflicting reports. If an uncoupled NOS is inhibited via L-NNA, this will decrease 
ROS/RNS production, leading to decreased activation of proliferative pathways. 
Additionally we believe uncoupled NOS is the driver of tumor progression and 
maintenance, not a normally coupled NOS which produces NO. Another example of this 
is shown in examining S-nitrosylated proteins. S-nitrosylation occurs when NO reacts 
with the thiol group from a cysteine. Proteins are analyzed using the biotin switch 
method (See Chapter 2, materials and methods), however this method can also 
recognize other forms of oxidized cysteines (unless performed with ascorbate as the 
reducing agent, as was done in this study). These other oxidized forms of cysteine, 
such as sulfonic and sulfenic acid, are formed by peroxynitrite and superoxide 
molecules [79, 80], not NO. Thus as mentioned earlier, if NOS is uncoupled, the 
proteins detected by the biotin switch assay, may in fact be oxidized forms of cysteine, 
we believe the interpretation of these results has been another reason for the seemingly 
contrasting effects of NO.  
In situations when NO donors are added cells with an uncoupled NOS generating 
O2-, this leads to the production of ONOO- leading to activation of proliferative and anti-
apoptotic pathways. However, as the concentration of NO donors is increased, this 
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leads to increased DNA damage and other NO dependent pathways which have been 
shown to decrease proliferation. Thus viewed in light of NOS coupling, conflicting 
results can be better understood. Uncoupled NOS is a driver of tumor progression and 
maintenance, thus by recoupling NOS with SP, we can decrease proliferation in vitro in 
colorectal cells. We will next examine the effects of SP on in vivo tumors developed 
using a murine colitis associated colorectal cancer model. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
  
 
 
 
Chapter 3: 
Recoupling NOS in vivo and Mechanism of NOS Uncoupling in Colorectal Tumors 
 
Introduction 
 The aims of the studies in this chapter are to use SP as a therapeutic agent for 
the treatment of colorectal cancer in vivo and to gain insights into mechanisms of NOS 
uncoupling. The previous chapter demonstrated that SP does have cytotoxic and anti-
proliferative effects in CRC cells via a decrease in β-catenin levels and activity. Thus we 
hypothesized in this model of CAC, administering SP therapeutically after tumor 
formation, should decrease proliferation of these tumors.   
Dextran Sodium Suflate (DSS) induced colitis and AOM induced colon cancer 
As discussed, inflammation provides initiating and promoting stimuli and 
mediators, generating a tumor-prone environment. For my studies I use an established 
model for colorectal inflammation leading to colorectal tumors [91].  Initially, animals are 
treated with azoxymethane (AOM, carcinogen) and subsequently given 3, one week 
cycles of DSS (see Figure 3.1). In between the DSS cycles, animals are put on normal 
drinking water. Tumors start to form during week 8 of DSS treatment cycle. In this 
animal model, DSS provides the inflammatory environment while a single exposure to 
AOM provides the initiating event. In combination the latency period for tumor 
development is dramatically reduced. This method of spontaneous tumor generation in 
mice mimics very closely the pathophysiology of CAC in humans such as with UC or 
Crohn’s Disease patients [91].  
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Figure 3.1: Azoxymethane and Dextran Sodium Sulfate Colitis Associated Colorectal Model. AOM is 
injected I.P. then the animals are started on three 1-week cycles of DSS. In between the cycles, normal 
drinking water is administered for 2 weeks, to allow for recovery from colitis. Tumors appear around 
week 8, but can vary.  
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 Previous studies in our lab have shown that, prophylactically, SP was able to 
decrease the degree colitis (and associated symptoms such as weight loss, diarrhea as 
well as damage seen histologically to the epithelium and tumor burden. We saw a 
decrease in inflammatory cytokines such as IL-1 and IL-6, decrease in nitrotyrosine 
staining in SP treated tumors (a hallmark of oxidative stress) and diminished tumor 
burden in SP treated animals [53]. However in these studies, SP was administered prior 
to colitis induction, rather than after tumor development. Thus due to our in vitro data in 
colorectal tumor cell lines, we decided to implement SP treatment in this CAC model 
after tumors were detected using /PET/CT imaging. 
For these studies we used FDG as the PET probe.  Animals are starved 
overnight since FDG is preferentially accumulated in highly metabolically active tissues. 
Tumors (and inflammatory tissues in general) generally take up FDG very quickly, along 
with brain and the heart. Kidneys and bladder are the main excretory pathway, thus on 
a typical scan, the heart, brain and tumor sites, along with urogenital tract will be “hot 
spots” allowing for the 3D-visualization of these tissues. This non-invasive technique 
allows us to analyze initiation and progression of the tumors, as well as monitoring the 
therapeutic effects of SP and a surrogate marker for tumor volume calculated via the 
FDG hotspot [92]. Thus with the spontaneously generated tumors we will be able to 
analyze the effects of SP, much as clinicians do in patients, as well as use classical ex 
vivo techniques to confirm imaging results. 
Potential Mechanisms of NOS Uncoupling 
 
Another valuable component of this CAC model is our ability to separate intact 
non-tumor colonic epithelial cells from tumor tissue. We have adapted a protocol 
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developed by Nik et al. [93] which separates intact colonic epithelium from 
mesenchymal layers of the colon. This technique allows for separate analysis of the two 
layers. We use this same technique to first remove colonic epithelial cells and then 
excise tumors for our analyses. Using this technique we can determine molecular 
differences between the tumor cells and their non-tumor counterparts, within the same 
animals (much like when tumorigenic and normal tissues are biopsied from patients with 
colorectal cancer). This technique may provide insight into how and why NOS is 
uncoupled in colorectal tumors.  
The question arises, how in fact do certain cells, such as myocytes after an 
infarct or tumor cells, become uncoupled. In myocytes, the answer may be a simple 
oxidation explanation, due to ischemia causing an increase in ROS/RNS and oxidation 
of BH4 to BH2 [94]. In this context, it is beneficial for myocytes which need to proliferate 
in order to survive the infarct. However after the infarct and ensuing inflammation 
mediated wound repair pathways are resolved, tissue homeostasis is restored and 
myocytes presumably return to a coupled state (unless of course a massive infarct 
occurred which caused death).  
However, tumor cells and other chronic inflammatory conditions may be different. 
These cells must enact mechanisms to maintain an uncoupled state. One explanation 
may be the infiltrating inflammatory cells providing ROS/RNS (or other signals) to 
remain in an oxidative state or even the oxidative microenvironment itself. However this 
explanation doesn’t account for the decreased BH4:BH2 we have measured in vitro, 
where these cellular components are lacking. Another component of the direct oxidation 
hypothesis may be an increase in ROS/RNS generating pathways, such as NADPH 
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Oxidases (NOX), within the tumor cells which perpetuates a low BH4:BH2 ratio [95]. 
Another possible mechanism maybe a molecular alteration in the BH4 metabolism 
pathway. These later two potential mechanisms can result in decreased BH4:BH2 ratios 
both in vitro and in vivo.   
Tetrahydrobiopterin Synthesis and Recycling  
BH4 synthesis and recycling is a well-regulated process dependent on many 
enzymes (Figure 3.2). Although there are several enzymes important in de novo 
synthesis and recycling of BH4, we have chosen to analyze four which are important in 
both pathways. GTP Cyclohydrolase-1 (GCH-1) is the enzyme responsible for 
catalyzing the rate limiting step in de novo synthesis. In previous work [42], we have 
shown that by over-expressing GCH-1 we are able to increase the BH4:BH2 ratio in 
MCF-7 breast cancer cells. Sepiapterin Reductase (SR, SPR) is an enzyme responsible 
for converting the final precursor of BH4, 6-Pyruvoyl Tetrahydrobiopterin to BH4 in the 
de novo pathway, but also converting BH2 (and SP) back to BH4 in the salvage 
pathway. Quinone Dihydropteridine Reductase (DHPR/QDPR) is also important in both 
the salvage and de novo pathways, much like SPR it is responsible for converting 
upstream pteridine derivatives into BH4. Lastly, GCH-1 Feedback Regulating Protein 
(GFRP) is an allosteric inhibitor GCH-1 [96]. There is evidence that in a variety of 
conditions, especially vascular endothelium dysfunction, alterations in pteridine 
metabolism causes altered recycling and de novo synthesis of BH4 [97-100].  Thus we 
hypothesized that these 4 proteins may be altered at the molecular level, resulting in 
decreased BH4 synthesis or decreased salvage of BH4 from BH2, leading to a 
decrease in BH4:BH2 ratio.  
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Figure 3.2: BH4 Biosynthsis and Salvage Pathways. The circled compounds are mechanisms by 
which researchers have shown can elevate BH4 levels in tissue culture or animals. Sepiapterin 
Reductase (SR) is an enzyme important in both the de novo and salvage pathway of BH4, as well as 
needed to convert  exogenous SP into BH4 
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Thus the studies in this chapter sought to determine if SP has therapeutic 
benefits in spontaneous CAC. FDG/PET imaging was used to determine when tumors 
arise, then start treatment with SP and use ex vivo techniques to determine the effects 
of SP on spontaneous tumors in mice. Experiments were also conducted to determine a 
mechanistic explanation of decreased BH4:BH2 ratios in these colorectal tumor cells. 
Inhibitors of ROS/RNS generating enzymes and ROS/RNS scavengers were used to 
see the effects of ROS/RNS within the tumor cells on BH4:BH2 ratio. Lastly, expression 
levels of GCH-1, GFRP, QDPR and SPR (in both mouse tissue and human RNA data) 
to determine if there are differences in biopterin metabolizing enzymes in tumor cells 
compared with normal colonic epithelial cells.  The combination of these two later 
studies provided plausible mechanisms for how NOS is uncoupled in colorectal tumors.  
 
 
    Materials and Methods 
 
A. Mouse model of colitis and colorectal carcinoma  
Long-term colitis/carcinogenesis was induced by the I.P. injection of AOM 
(10mg/kg) seven days prior to the onset of DSS treatment. Three, 5-7 days long 
each (depending on weight loss of animals), courses of 2% DSS were given as 
above separated by 2 weeks of DSS-free water. All animals were monitored daily 
for weight, stool consistency and the presence of blood in the excreta.  Disease 
activity index (DAI) was determined by combining scores for weight loss, stool 
consistency and bloody excreta as follows:  Weight loss (0: <1%, 1: 1-5%, 2: 5-
10%, 3:10-15%, 4: >15%); Stool consistency (0: normal, 2: loose, 4: diarrhea); 
Blood in excreta (0: normal; 2: reddish, 4: bloody). Usually by day 5 on 2% DSS 
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animals lost ~10% of body weight and showed signs of gastrointestinal stress. 
Mice designated for SP treatment received either the long term SP course: 
10mg/kg via drinking water for 3 weeks or short course: 3 daily doses for a total 
dose of 10mg/kg via oral gavage for 8 day treatment course.   All animals were 
monitored daily for weight, stool consistency and the presence of blood in the 
excreta.  All procedures were approved by the Institutional Animal Care and Use 
Committee of Virginia Commonwealth University and conformed to the guidelines 
established by the National Institutes of Health, protocol numbers AM10080 and 
AM10185. 
B. Western Blot Analysis 
Protein was extracted from flash frozen tumors excised from colons using a 
pestle and mortar in 20 ml/g tumor RIPA lysis buffer (50 mM Hepes pH 7.4, 150 
mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 5 mM EDTA) 
and processed under reducing conditions. Proteins were resolved by SDS-
polyacrylamide gel electrophoresis and transferred to nitro-cellulose membranes. 
Membranes were incubated with the primary antibody of interest overnight at 
4°C. Blots were developed using IR 700 or IR 800 conjugated secondary 
antibodies (Rockland Immunochemicals, Gilbertsville, PA) diluted 1:10,000 and 
imaged/analyzed using the Odyssey Licor system. 
 
C. Histopathology and Immunofluorescence Staining 
Colons were excised from animals, flushed with PBS, cut longitudinally, rolled 
into “swiss rolls” and immediately flash frozen in liquid N2. Tumors were also 
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excised separately, rinsed in PBS and flash frozen.  Frozen Swiss rolls or 
excised tumors were embedded in OCT and cryosections prepared.    
For β-Catenin detection, frozen sections were fixed in ice-cold acetone for 10 
min.  After blocking with goat serum blocking for 60 min, the sections were 
stained with primary monoclonal antibody for β-Catenin (BD Biosciences Catalog 
#, 610154) overnight at 4oC, followed by incubation with Alexa488-labeled goat 
anti-mouse secondary IgG (Invitrogen) at RT for 1 hour. A negative staining 
control was performed by incubation with isotype control Abs. 
For Hematoxylin and Eosin (H&E) staining, cryosections (20 m) were fixed in 
4% paraformaldehyde, submerged in Modified Mayer’s Hematoxylin (Richard 
Allan Scientific), destained in acid ethanol, stained with eosin, dehydrated and 
mounted with permount.  Images were captured using the Ariol Digital Pathology 
Platform.  
For ApoTAG Staining, a kit was purchased from Millipore (Catalog# S7111). 
Sections from excised tumors were fixed and stained according to the protocol 
accompanying the kit.    
 
D. PET/FDG Image Acquisition and Analysis.  
 
Fasted and anesthetized (2% isoflurane in Oxygen) animals were tail vein 
injected with 300 µCi [18F]FDG from IBA Molecular, (Sterling, VA).  After 60 
minutes of FDG uptake, animals were positioned in the Inveon Preclinical 
System (Siemens Healthcare, PA) and PET/CT images acquired for 10 minutes 
with no attenuation correction. The PET images were processed using 
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manufacturer recommended calibration procedures and a phantom of known 
volume and activity acquired prior to the study. OSEM3D-MAP reconstructions 
were done using Inveon Acquisition Workplace 1.5 and were used for region-of-
interest (ROI) analysis in the Inveon Research Workplace 4.1. The percent 
injected dose/gram of tissue (%ID/g) values were calculated after appropriate 
decay corrections using the formula, %ID/gm = Ct/ID x 100, where Ct is the 
concentration of radiotracer in the tissue (MBq/cc), obtained from the PET 
images after ROI analysis. 
F. Separation of intact colonic epithelial cells from mesenchymal layer 
Colons were excised (see chapter 3 section D). After cleansing and rinsing in 
PBS, the excised colon was carefully slid onto oral gavage needle with a 5cc 
syringe drawn with air. The distal end of the colon was slid on first, and the 
proximal end of the colon ended up at the tip of the needle. The proximal end 
was tied using surgical sutures at the tip. At the tied end, the colon was 
carefully inverted up on itself, until eventually the distal of the colon is now 
hanging off the needle, and the whole colon is inverted. The distal end is then 
tied off with suture. The colon is carefully inflated with air.  In 15mL conical 
tubes, 1 mL of Cell Separation Solution (part number) is incubated on ice and 
the inverted, inflated colon is submerged in separation solution for 15 
minutes. Every 5 minutes, the air is drawn from the balloon and the colon re-
filled. After 15 minutes, the colonic villi are carefully scraped from the 
mesenchymal layer using a scalpel into cold PBS, allowing for analysis of 
separated epithelial cells.  
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G. RNA Isolation and qPCR Gene Expression Analysis 
 
RNA from extracted colonic epithelia cells was obtained using RNeasy Kit from 
Qiagen and stored at -80o C. cDNA was made from the extracted RNA fresh on 
the day RT-PCR was to be performed using iScript cDNA Synthesis Kit from Bio-
Rad and 1ug of RNA. Primers were made using Integrated DNA Technologies 
Primer Design Program for qPCR Assays (www.idtna.com) for SPR, GCHRF, 
GCH1, and QDPR. The sequences used for each are:  
SPR For: 5’ CTGAGGAACCGAGTGTGC-3’ and Rev: 5’-
CCCATCCGACTTCAACTTCTG-3’ 
GCHFR For: 5’-CATCAGCACTCAGATCCGTATG-3’ Rev: 5’-
GGGTCGTTGACGTAGTATTCG-3’  
GCH-1 For: 5’-GCATCACCTTGTTCCATTTGTAG-3’ Rev: 5’-
AGGCGCTCTTGAACTTGTAG-3’  
QDPR For: 5’-GTTGGAAAGCTCCTAGGTGAC-3’ Rev 5’-
GTGGCTGGAGATAGTGGATG-3’ 
The primer sets were then ordered from Eurofins. Quantitative RT-PCR was 
performed using the FastStart Universal SYBR Green Master Mix RT-PCR Kit 
(Roche). 100 ng of cDNA was used for each 25 µl real-time RT-PCR reaction. 
The housekeeping GAPDH gene transcript was used to normalize mRNA 
gene expression. Real-time PCR was performed by a 7500 Fast Real-Time 
PCR System (Thermo Fisher Scientific). The PCR protocol conditions were 
as follows: 50°C hold step then 95°C for 10 min, followed by 40 cycles of 
95°C for 15s and 60°C for 60s. A melting curve analysis was performed using 
the software’s SYBR green protocol to ensure no primer-dimer were made 
and the reactions were successful.  
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H. mRNA Analysis from Matched Tumor-Normal Colon Patient Samples 
Log transformed data for tumors and their corresponding normal tissue 
expression data was obtained from The Cancer Genome Atlas (TCGA) Data 
Matrix. Mike Waters, (MD/PhD Candidate from Dr. Tomek Kordula’s Lab) 
acquired and analyzed the data for this comparison.  
 
 
Results: 
Sepiapterin raises BH4:BH2 ratios in vivo leading to decreased tumor associated 
FDG activity and tumor size 
After the final round of DSS, animals were placed back on normal drinking water for two 
weeks to allow for the symptoms of colitis to subside. After two weeks, a group of 
animals (N = 9) was treated with 10mg/kg SP for 3 weeks administered in drinking 
water, while control animals (N =10) were kept on normal drinking water. Animals were 
first imaged at the end of week 9 before any treatment and then subsequently every 
week. All animals were sacrificed at the end of week 13 (5 weeks after completion of 
last DSS round). We excised tumors from each group of animals to perform ex vivo 
analyses. We first wanted to measure BH4:BH2 ratios in this spontaneous CAC model, 
Figure 3.3 shows that indeed SP was able to raise the BH4:BH2 ratio almost 4 fold in 
our SP treated animals as compared to control tumors. We next examined gross 
differences in SP treated versus non treated animal colons. Figure 3.4 shows that SP 
treated animals had less tumors than control animals and relatively smaller tumors.  
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Figure 3.3: BH4:BH2 Ratios Measured in C57Bl/6J Mice with Spontaneously Generated CAC 
Tumors. BH4:BH2 Ratios were measured in vivo colorectal cancer tumors using HPLC. Animals 
were treated 10mg/kg/L in drinking water with SP for 3 weeks. Values are given ± SEM (N = 5 
control animals and 5 SP treated animals).  
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Figure 3.4: Gross comparison of SP Treated versus Non treated CAC Tumors. At 10 weeks post 
AOM injection (2 weeks post final DSS treatment) SP treated animals were administered with 
10mg/kg/L in drinking water with SP for 3 weeks. Control and treated animals were sacrificed and 
colons harvested for tumor analysis. Although the effects of SP varied on tumor growth, overall SP 
decreased size and number of tumors when compared with untreated animals. Representative 
images are shown (N = 5 control animals and 5 SP treated animals) 
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The tumors in control animals were also visually redder (possibly more inflamed) in 
color when compared to SP treated animals. Lastly, we observed that SP treated 
colonic tissue was less fragile that control tissue, control colons were easily torn during 
dissections.  We next sought to corroborate what we had seen on gross dissection with 
FDG/PET images we had acquired of the SP treated and control animals. Figure 3.5A 
shows the results from 3 SP treated and control animals after two weeks of SP 
treatment. The numbers in parentheses represent FDG uptake from our colonic tumor 
regions of interest, pre and post SP treatment. Figure 3.5B is the cumulative change in 
FDG uptake between week 9 and week 11 (2 weeks post SP treatment). Control 
animals show about a 50% increase in FDG uptake in that two week time span, 
whereas SP treated animals show 25% decrease in FDG uptake in the same time span. 
Thus SP treatment at two weeks was able to decrease FDG uptake. In this animals, SP 
was administered in the drinking water, however this made the exact amount of SP 
each animal received nearly impossible to measure. We also realized the need to 
measure FDG uptake at an earlier time point. We decided to address these issues by 
administering SP treatment via oral gavage, 3 times daily for only 8 days. In this 
treatment course we again used FDG/PET to follow tumor growth and drug effect. We 
scanned 10 animals at week 12, then again at week 14, then 3 days into SP treatment 
and a final scan at 8 days of SP treatment. Figure 3.6A shows FDG/PET images of two 
representative animals. The red rectangles represent tumor regions of interest that we 
followed during the treatment course. Figure 3.6B shows before SP treatment, FDG 
uptake increased almost two fold from baseline, but after 3 days of SP treatment there 
was about a 30% decrease in FDG uptake from baseline  
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Figure 3.5: FDG/PET Images of C57Bl/6J Mice with long term SP 
Treatment. At 10 weeks post AOM injection (2 weeks post final DSS 
treatment) SP treated animals were administered with 10mg/kg/L in 
drinking water with SP for 3 weeks. Animals were imaged weekly and 
tumor progression was followed. A) Images are from 3 animals in each 
group at week 9 and again after 2 weeks of SP treatment. (H= Heart, K = 
Kidneys, B = Bladder, T = Tumor region of interest) B) FDG Uptake values 
were calculated and the percent change from baseline was calculated 
and averaged (also shown in parenthesis in (A) images). These values 
show a decrease in uptake values in SP treated animals, while control 
animals increased FDG uptake in that time span. (N = 5 control animals 
and 5 SP treated animals) 
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Figure 3.6: FDG/PET 
Images of C57Bl/6J Mice 
with short term Oral 
Gavage SP Treatment. At 
10 weeks post AOM 
injection (2 weeks post final 
DSS treatment) SP treated 
animals were administered 
with 3.33 mg/kg/L 3 
times/day for 8 days. 
Animals were imaged 2 
times before SP treatment, 
then after 3 days and 8 
days of SP Treatment. (Red 
rectangle outlines tumor 
region of interest, B = 
Bladder) B) FDG Uptake 
values were calculated and 
normalized to the fold 
change from week 10 and 
averaged for N = 10 
animals. Fold change values 
are shown with ± SEM. * p 
≤ 0.05 using Student t-test 
was calculated between 
9Mar FDG uptake and 3 or 
8 days of SP treatment.  
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which was sustained at day 8 as well. When compared with our earlier two week SP 
treatment data (Figure 3.3) the shorter term oral gavage treatment efficacy is very 
similar. However, with oral gavage the exact amount of SP given to each animal is 
known and all animals showed a decrease in FDG uptake after 3 and 8 days of SP 
treatment. These data also show that, short term SP treatment has about the same 
efficacy as longer term treatment.  
Sepiapterin leads to increased apoptosis and decreased β-Catenin expression in 
CAC tumors  
We next sought to correlate our imaging and gross results with ex vivo analysis of 
excised CAC tumors that were treated with SP in drinking water for 3 weeks.  We first 
examined apoptosis using the ApoTAG kit from Millipore. Figure 3.7A shows 
representative tumor sections from control and SP treated animals. SP treated animals 
showed an increase in apoptosis when compared with control animals. Figure 3.7B is 
the quantification for apoptosis staining in these tumors. We next sought to corroborate 
our in vitro findings with SP treatment and its effects on β-catenin expression. In in vitro 
experiments, SP treatment led to decreased β-catenin expression and Figure 3.8 shows 
that SP treatment led to decreased β-catenin expression both in tumor sections and 
tumor homogenates via western. Thus we have seen that SP leads to decreased β-
catenin expression both in vitro and in vivo. Lastly, we sought to determine if SP has 
any effects on the expression of Vimentin. Vimentin is an important marker of the 
epithelial to mesenchymal phenotype tumor cells undergo as the tumor progresses from 
a differentiated cell to a more malignant cell. We again used our 3 week treated SP 
treated tumor sections. As seen in Figure 3.9, after treatment with SP for 3 weeks,  
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A.  
B.  
Figure 3.7: Ex Vivo Analysis of Apoptosis in CAC Tumors. At 10 
weeks post AOM injection (2 weeks post final DSS treatment) SP 
treated animals were administered with 10mg/kg/L in drinking 
water with SP for 3 weeks. After treatment, animals were 
sacrificed and their colons removed. Tumors were excised from 
colon and histological slides were made and stained using 
ApoTAG Kit from Millipore. A) Representative sections are shown, 
with ApoTAG staining in green and Hoescht stain for nuclei in 
blue. B) Quantification was done by obtaining  green:blue ratios 
(green ApoTAG staining to blue nuclei staining to account for size 
differences in tumors). Ratios were then averaged within Control 
(N =5) and SP treated animals (Tx) (N = 4) groups. Averaged ratio 
of controls was normalized to 1 and fold change was compared 
to SP treated animals. Values are shown ± SEM, * p ≤ 0.05.  
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Figure 3.8: Ex Vivo Analysis of β-catenin in CAC Tumors. At 10 
weeks post AOM injection (2 weeks post final DSS treatment) SP 
treated animals were administered with 10mg/kg/L in drinking 
water with SP for 3 weeks. After treatment, animals were 
sacrificed and their colons removed. Tumors were excised from 
colon and histological slides were made and stained using for β-
catenin expression. A) Representative sections are shown, with 
β-catenin staining in green and Hoescht stain for nuclei in blue. 
B) Quantification was done by obtaining  green:blue ratios (green 
β-catenin staining to blue nuclei staining to account for size 
differences in tumors). Ratios were then averaged within Control 
(N =5) and SP treated animals (Tx) (N = 4) groups. Averaged ratio 
of controls was normalized to 1 and fold change was compared 
to SP treated animals. Values are shown ± SEM. C) Western blot 
analysis, whole tumor homogenates from control or SP treated 
animals were analyzed for β-catenin expression levels.  
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Figure 3.9: Ex Vivo Analysis of Vimentin CAC Tumors. At 10 weeks post AOM injection (2 weeks 
post final DSS treatment) SP treated animals were administered with 10mg/kg/L in drinking water 
with SP for 3 weeks. After treatment, animals were sacrificed and their colons removed. Tumors 
were excised from colon and histological slides were made and stained using for Vimentin 
expression. A) Representative sections are shown, with vimentin staining in green and Hoescht 
stain for nuclei in blue. B) Quantification was done by obtaining  green:blue ratios (green vimentin 
staining to blue nuclei staining to account for size differences in tumors). Ratios were then 
averaged within Control (N =5) and SP treated animals (Tx) (N = 4) groups. Averaged ratio of 
controls was normalized to 1 and fold change was compared to SP treated animals. Values are 
shown ± SEM. C) Western blot analysis, whole tumor homogenates from control or SP treated 
animals were analyzed for β-catenin expression levels.  
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vimentin expression was not visually or statistically different between treated or control 
animals.  
An oxidative environment and altered levels of biopterin metabolizing enzymes 
contribute to a decreased BH4:BH2 ratio 
We first wanted to compare the levels of important enzymes in both the de novo 
synthesis and salvage of BH4 in normal colonic epithelial cells from non-tumor bearing 
animals with tumors from animals treated with AOM/DSS. Figure 3.10A is qPCR 
analysis of GCH-1, GRFP, QDPR and SR. After normalization to GAPDH mRNA and 
quantification, we saw that there were significant differences in GCH-1 and SR mRNA 
levels. GCH-1 mRNA was greatly upregulated, whereas SR mRNA was decreased. We 
next sought to correlate our transcript analysis with protein analysis using western blots 
in the same tumor tissues and normal colonic epithelial cells. Figure 3.10B shows 
western blot analysis of the four molecules. The first obvious fact is there is great 
variability from one tumor to the next. This is most likely due to this model of 
spontaneous tumor development, and the heterogeneity of the tumors within and across 
animals. These tumors arise at different times during the DSS treatment course, thus 
are at different stages. Aside from that fact, the western blot data does not seem to fit 
with our qPCR analysis very well either. It seems protein levels of QDPR are decreased 
in the tumors, whereas mRNA levels of QDPR are unchanged. Proteins levels of SR are 
elevated in tumor tissue, whereas the mRNA levels of SR were significantly decreased. 
In two tumors, GCH-1 levels are elevated, whereas in another two they are not. Lastly, 
GRFP protein levels seem to be decreased when compared with normal epithelial 
tissue. A caveat with this data is that the qPCR uses 10 tumors and 5 normal epithelial  
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Figure 3.10: Expression Analysis of Biopterin Metabolizing Enzymes in C57Bl/6J Mice with CAC 
Tumors. Using the colonic epithelium separation technique, we separated normal epithelium 
(NE) and Tumors (T) from AOM/DSS treated animals. RNA and Proteins were extracted from NE 
and T from 3 animals (two tumors from animal 3 were used) A) qPCR was conducted to analyze 
for transcript levels of GTP Cyclohydrolase 1 (GCH-1), GCH Regulating Factor Protein (GCHRFP), 
Quinone Dihydropteridin Reductase (QDPR) and Sepiapterin Reductase (SPR, SR) Values are 
normalized to GAPDH levels and shown ± SEM. B) Western blot analysis of the same four 
enzymes.  
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tissue samples, whereas the western blot analysis uses tumors and normal tissue from 
3 animals each. 
We next sought to analyze these same four enzyme mRNA levels in tissue 
samples from human patients using The Cancer Genome Atlas’s (TCGA) database. We 
compared normal colonic tissue expression and tumor tissue levels of these 4 
molecules. In this analysis, (Figure 3.11) we saw only two of the four molecules had 
significant differences between normal and tumor tissue. GFRP mRNA levels were 
significantly increased and SPR levels were significantly decreased. Although it is not 
possible to correlate mRNA levels with protein levels in these samples, if we assume 
GFRP levels are increased this would inhibit GCH-1 and decrease BH4 de novo 
synthesis. If Sepiapterin Reductase levels are decreased, this would decrease recycling 
of BH2 back to BH4 via the salvage pathway (also decrease de novo synthesis because 
SR catalyzes a step in that pathway as well). Thus the end result of the change in 
enzyme levels of these two molecules will lead to decreased BH4 levels and a 
concomitant increase in BH2 levels.  
 In order to assess the effects of ROS/RNS generating mechanisms within the 
colorectal tumor cells, we used inhibitors and scavengers of ROS/RNS to determine 
their effects on BH4:BH2 ratios. L-NG-nitro-L-arginine (LNNA) is a specific inhibitor of 
NOSs, GP91 is a small peptide inhibitor of NADPH Oxidases, which generate 
superoxide molecules and EUK134 is a scavenger of superoxides and peroxinitrite. 
Table 3.1 shows the effects of BH4:BH2 ratio using these inhibitors of ROS/RNS alone 
and in combination. In all cases there was a slight increase in the BH4:BH2 ratio  
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Figure 3.11: Expression Analysis of Biopterin Metabolizing Enzymes in Human Colorectal 
Samples and normal colonic tissue. Using The Cancer Genome Atlas (TCGA) database we 
obtained expression data from patients with colorectal cancer who had biopsies of colorectal 
tumors with expression data for normal colonic tissue in biopterin metabolizing enzymes.  
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Table 3.1: BH4:BH2 Ratios after inhibition of sources of ROS/RNS. 
Comparison of BH4:BH2 ratios after treatment of HCT116 cells with 
specific inhibitors of ROS/RNS.  L-NG-nitro-L-arginine (LNNA) was 
used to inhibit NOS, 200nM for 24 hours. EUK134, Superoxide 
Dismuatase Mimetic, was used at 10uM for 24 hours. GP91, NOX 
inhibitor, used at 5uM for 3 hours. Values are given ± STD. 
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when compared to untreated HCT116 cells, with the greatest increase when all three 
molecules were used together.   
Discussion:  
The first section of this chapter focused on examining the effect of SP treatment had in 
animals which had undergone spontaneous colorectal tumor development. SP 
treatment in mice with colorectal tumors led to an increased BH4:BH2 ratio, signaling 
towards a coupled NOS. In both short term oral gavage therapy and long term SP in 
drinking water, we saw decreased FDG uptake, a surrogate marker for metabolic 
activity. On gross examination we saw decreased tumor size and number in treated 
animals. Ex vivo analysis showed that SP treatment increased apoptosis and a 
concomitant decrease in β-catenin expression levels. We did not see a decrease in 
vimentin expression, a marker for epithelial to mesenchymal transition (EMT). Due to 
the loss of β-catenin expression, we believe the mechanism to be similar to what was 
seen in vitro (Chapter 2). SP treatment leads to a recoupling of NOS (due to the 
increase in BH4) which leads to an increase in NO. This would shift the cellular 
signaling from proliferative/anti-apoptotic pathways which rely on superoxide and 
peroxinitrite, towards NO mediated pathways. As shown by our earlier work and others, 
NO can S-nitrosylate AKT leading to a decrease in its activity. Loss of AKT activity will 
lead to increased GSK3β activity and a decrease in β-catenin expression levels. AKT 
also regulates many other cellular metabolic pathways, such as glucose uptake into 
cells [101, 102]. Thus one reason for the decrease in FDG uptake (along with a 
decrease in tumor size and number seen on gross examination) may be decreased AKT 
activity causing decreased GLUT4 translocation. The loss of AKT activity leads to 
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decreased proliferation and increased susceptibility apoptotic signaling. Thus we 
believe that SP in combination with ionizing radiation (IR) can have radio-sensitizing 
effects on tumor cells. Preliminary work in our lab has shown that indeed, SP in 
combination with IR can be more cytotoxic than just IR or SP alone. However, due to its 
antioxidant effects, SP cannot be present during radiation treatment. We are currently 
working to determine the most efficacious treatment schedule of SP and IR. We also 
noticed that after 3 weeks of SP treatment, the response to SP seems to diminish with 
prolonged exposure, another reason to combine SP with other chemotherapeutic drugs 
and/or IR.  
 In our prolonged SP treatment, we also noticed variable response to SP 
treatment. Some animals responded very well to treatment, whereas others only saw a 
plateauing effect on FDG uptake. Upon gross examination, the tumors from SP treated 
animals were smaller and less in number but this varied from animal to animal. Thus we 
decided to treat animals via oral gavage with 3 daily doses of SP. This would address 
the potential problems that some animals received more SP than others and the 
difficulty to know exactly how much SP each animal received when SP was delivered 
through the drinking water.  However, even with oral gavage delivery of the same 
dosage of SP to all animals and with all animals demonstrating a decrease in FDG 
uptake (although the time points were 3 and 8 days) the overall response still varied. 
One explanation may be due to differences in SR levels, as seen in Figure 3.8B. We 
saw varying amounts of SR levels thus SP is metabolized to BH4 differently in each of 
these tumors. It is important to stress that due to the heterogeneous nature of this 
model, the tumors are all at different stages of development, which may have an effect 
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on response. In our short term treatment course, we see that SP’s greatest effect was 
after 3 days of treatment, which would have been missed with the longer treatment 
course. This may also explain the lack of effect of vimentin expression. Perhaps SP 
changes EMT markers early in the treatment and over time the tumor is able to become 
more resistant to SP. We measured vimentin expression in tumors which had been 
treated for 3 weeks. Current studies are underway in our lab to examine SP’s effect on 
EMT markers as well as vascularization in shorter SP treatment course in CAC. Future 
studies are also underway to determine NOS uncoupling in infiltrating immune cells in 
the tumor microenvironment. Specifically we wish to analyze the coupling state of tumor 
associate macrophages (TAM) which play important roles in providing cytokines and 
growth factors to allow for maintenance and progression of the tumors. A strength of our 
DSS/AOM colorectal cancer model is that we can follow progression of the tumors and 
monitor the effect of inflammatory cells on tumor growth and development. iNOS is 
resistant to uncoupling via a drop in BH4:BH2 ratio [34] however can be uncoupled due 
to a decrease in arginine levels. Another important finding has been zinc ion levels can 
affect iNOS function and expression in a variety of immune cells. Zinc levels also play 
roles in NO availability and elevated levels can lead to apoptosis. Perhaps by recoupling 
NOS zinc levels are altered and can lead to apoptosis in tumor cells, as well as activate 
the immune cells against the tumor cells [103].  
In this chapter we also sought to determine possible mechanisms of how the 
BH4:BH2 is altered in tumor cells. In order to determine possible mechanisms of a 
decrease in BH4:BH2 ratio, we used inhibitors for NOS, NOX and scavengers of 
ROS/RNS, as well as changes in expression of enzymes involved in biopterin 
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metabolism We analyzed mRNA and protein levels of 4 proteins important in the de 
novo and salvage synthesis of BH4 in both normal colon epithelial cells as well as tumor 
cells from tumor bearing animals. Using this spontaneous CAC model, we saw 
increased GCH-1 mRNA levels, decreased SR mRNA levels. QDPR and GFRP mRNA 
were not significantly different between normal and tumor tissue. Next we analyzed 
protein expression using western blot, hoping to corroborate our mRNA data. Instead 
we saw, in general, an increase in SR in tumor tissue (although there was variable 
amounts of SR in each tumor), decreased GFRP in tumor tissue, similar amounts of 
QDPR (although the protein may be of different size in the different tissue type) and 
varying amounts of GCH-1 between the 4 tumors. One possible explanation for the 
increased GCH-1 and SPR and reduced GFRP expression levels is that this is the futile 
response of the tissue to maintain a high BH4:BH2 under chronic inflammatory 
conditions.  While I have shown with inhibitors of NOS and NADPH oxidase that ROS 
generated from these activities contribute to the low BH4:BH2 they by themselves 
remain insufficient to completely account for low BH4:BH2.  Planned experiments will 
measure the enzymatic activities of GCH1, SPR and QDPR.  We also plan to measure 
expression levels of cellular adhesion proteins (e.g. VCAM-1) that may facilitate 
recruitment of inflammatory cells to the colon and whether SP treatment by inhibiting 
NFκB activity reduces cellular adhesion protein expression or  whether reducing 
inflammatory cells with for example anti-GR1+ to deplete animals of neutrophils will 
more substantially enhance BH4:BH2. Finally, one major concern, is the small number 
of animals we used to conduct this experiment. We are currently treating another batch 
of animals to conduct a more thorough study. Another concern is that the tumors in 
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these animals are heterogeneous and arise at different time points, thus some may be 
relatively “younger” whereas others may have arisen much earlier. There is 
considerable difference in their sizes as well. Thus this model may not be the ideal 
model to study biopterin metabolizing enzyme differences. We also plan to conduct 
similar experiments in MMTV mice which develop breast carcinomas and compare with 
normal mammary fat pad tissue with tumor tissue. There may also be post 
transcriptional regulation of the mRNA transcripts in tumor tissue, which may account 
for the differences seen via western blots. Another factor which must be considered in 
future studies is also the relative activities of these molecules in tumor tissue versus 
normal epithelial cells. The activities of these enzymes may also be perturbed, with or 
without a concomitant change in expression levels.  
 We also measured expression levels of these enzymes in human patient 
samples of normal colonic epithelial cells and colorectal tissues. In human patient 
samples, we also noticed SR mRNA levels were decreased and GFRP mRNA levels 
were increased. QDPR and GCH-1 were not significantly altered. If we assume 
decreased expression of SR and increased GFRP protein levels, this would lead to an 
increase of BH2 in tumor cells. Future studies must be done to corroborate this finding 
using western blot to see protein expression changes in tumors from patients.  
 Using LNNA, gp91 NOX inhibitor and EUK134 (SOD mimetic) we were able to 
raise BH4:BH2 slightly as compared to untreated colorectal cancer cells. When we 
combined all three molecules, we saw the greatest increase in ratio from 2.3, to about 
3.1. Although this a slight increase, it does demonstrate that the oxidative environment 
plays a role in diminishing BH4 levels. There are other sources of ROS/RNS within the 
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cells such as mitochondria, which when inhibited may contribute to increasing the 
BH4:BH2 ratio. We plan on developing ρ-HCT-116 cells (lacking functioning 
mitochondria) to determine the impact of mitochondrial ROS/RNS generation on 
BH4:BH2 ratio. 
 Our current data shows that alteration of biopterin metabolizing enzymes and 
ROS/RNS generating pathways play a role in decreasing the BH4:BH2 in these cancer 
cells. Perhaps the initial infiltration from inflammatory cells, which produce large 
amounts of ROS/RNS lead to a dramatic drop in BH4:BH2 ratio which then activates 
proliferative pathways and lead to the accumulation of more mutations. Perhaps this 
initial drop in BH4:BH2 leads to changes in the biopterin metabolizing enzymes 
themselves, eventually leading to a more permanent drop in BH4:BH2 ratio. The 
activation of oxidative signaling pathways as shown in chapter 2, are clearly 
advantageous to tumor cells, thus selected for to advance growth and progression. 
Earlier work in our lab using the CAC tumor model, demonstrated when SP was given 
to animals from the start of AOM/DSS cycles, there was decreased tumor burden in the 
animals. Thus a coupled NOS decreased tumor initiation in this model. However, like 
most monotherapies, tumor cells can find a way around them and adapt. Thus our 
future plans with sepiapterin are to combine with other chemotherapeutic drugs and 
ionizing radiation in order to determine if SP can increase efficacy of traditional cancer 
therapies.  
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Chapter 4: 
Perspectives and Future Directions 
 Through the course of this dissertation, we have shown both in vitro and in vivo 
that SP leads to an increase in BH4:BH2 ratio and a decrease in proliferative pathways 
in colorectal tumor cells. We have also sought to explain the mechanism by which tumor 
cells sustain a decrease in the BH4:BH2 ratio. Although SP is able to decrease tumor 
size and activity in vivo, monotherapies are not the best tools in combating cancer. 
Preliminary studies in our lab have shown that SP can be combined with radiation to 
increase tumor cell killing.  
Using Nitric Oxide, BH4 or SP as Cancer Therapeutics 
 A major goal of these studies was to confirm SP (by recoupling NOS and 
increasing NO levels) has anti-tumor effects. As mentioned earlier, NO and NOS has 
been shown to play a role in both tumor initiation and progression. In our own lab, we 
have shown L-NNA, an inhibitor of NOS, has anti-tumor effects when combined with 
radiation [81]. We believe that since the coupling state of NOS determines whether NO 
or detrimental ROS/RNS are produced, therapeutic effects of NOS inhibition, NO 
donors, or SP must be considered the coupling state of NOS in mind. In many cases, 
NO donors or NO donors combined with NSAIDs have been shown to have anti-tumor 
effects. NO-ASA was shown to be an effective releaser of NO and treatment of HCT116 
and HT-29 colon cancer cells resulted in inhibition of growth [82].  The results showed 
that the NO released modified a number of cell signaling members key in tumor cell 
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signaling, including NFκB, β-catenin and p53, all of which were shown to be S-
nitrosylated [82, 85, 104, 105]. The NO donating prodrug, O2-(2,4-dintrophenyl) 1-[(4-
ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) is another NO donating 
compound that has shown promise as an anti-oncogenic agent in leukemia, renal, 
prostate and brain cancer cells [106, 107].  Thus if an uncoupled NOS is inhibited, as in 
our study with L-NNA, this causes tumor cell killing. Also if the NO concentration in the 
tumor cells is increased where some proteins in proliferative pathways are S-
nitrosylated, e.g. NFκB, this will lead to inhibition of growth and cell death.   
 An important caveat to using NO or SP as a potential therapeutic is the effect on 
tumor vascular effects of these molecules. NO and eNOS expression has been shown 
to increase VEGF and HIF-1 expression [108, 109]. NO can also lead to increased 
COX-2 expression leading to increased vascular permeability and increased 
angiogenesis [84]. The combination of these may increase 
vasculogenesis/angiogenesis in the tumor, which potentially can increase tumor growth. 
Thus NO or SP should not be used as a monotherapy. However this increased 
vascularity should increase tumor reoxygenation, which when combined with radiation, 
should increase tumor cell killing. The same argument applies to anti-tumor drugs, 
increased vascularity as a result of SP treatment also enhances drug delivery to the 
tumor.  Importantly, SP treatment while significantly increasing BH4:BH2 in tumors is 
unlikely to have any significant effect on the already high BH4:BH2 in normal tissues.  
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Tumor Revascularization using SP 
 The tumor vasculature is very disordered, leaky and maintains hypoxia, 
especially at the core of the tumor. Hypoxia increases radio-resistance in tumor cells. A 
disordered and leaky vasculature also allows for invasive cells to migrate and 
metastasize to distant organs. Another advantage of a disordered vasculature is 
decreased drug delivery. One of the reasons for a disordered vasculature has been 
attributed to tumor endothelial cells (TECs) which are distinct from normal endothelial 
cells. TECs have been shown to have increased doubling times, larger nuclei, display 
aneuploidy, increased responsiveness to growth factors, more motile and invasive 
compared with normal endothelial cells. TECs have also been shown to be activated 
after radiation to increase pro-survival pathways such as STAT3 and PKCε. Thus we 
believe that TECs can increase radio-resistance of tumors. In our lab we used 2H11 
mouse TECs to study the effects of SP after radiation in these cells. Figure 4.1 shows 
STAT3 and PKCε activation of IR in 2H11 cells. We believe the activation of these and 
other pro-inflammatory pathways increases radio-resistance of their adjacent tumor 
cells. We have also seen that radiation activates STAT3 in A549 and HCT-116 cells. 
Figure 4.2 shows SP treatment with IR decreases the activation of STAT3 in 2H11 cells. 
We also used confocal imaging to analyze for stress fiber formation (a marker for 
endothelial cell activation) after radiation. Figure 4.3 shows that IR increases stress fiber 
formation, but SP treatment decreases the formation of stress fibers. Lastly, we 
examined migration of 2H11 cells after radiation. Figure 4.4 shows that after IR, 2H11  
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Figure 4.1 Ionizing Radiation Activates Survival Molecules in 2H11 TECs. 2H11 TEC were 
treated with 5 Gray IR and analyzed for increase in proliferative markers (A) PKCε and (B) 
STAT3 Serine 727 phosphorylation. S-Nitroso-N-Acetyl-D,L-Penicillamine (SNAP) NO donor 
was used as a positive control.  
A. 
B. 
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Figure 4.2: SP Treatment of 2H11 TECs before IR Decresed STAT3 Phosphorylation. 2H11 TECs were 
treated with 20uM SP for 24 hours, then irradiated at 5 Gray. STAT3 Serine 727 was decreased with SP 
treatment.  
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Figure 4.3: Stress Fiber Formation after IR. 2H11 TECs were treated with 5 Gray IR, and/or 20uM of SP 
for 24 hours. Stress fiber formation was assessed using staining for Acin-F and imaged using confocal 
microscopy. Phorbol ester (TPA) was used as a positive control. SP pre-treatment decreased the 
formation of stress fibers after IR.  
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Figure 4.4: Migration Assay after IR 
Treatment. 2H11 TECs were grown to 
near confluence, then irradiated at 5 
Gray. At 12 hours, untreated cells nearly 
closed 70% of gap, whereas 20uM SP 
treated cells, or cells with 10uM PKCε 
Inhibitor only closed about 30% of gap.  
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cells increased motility, however using SP, we were able to decrease the migration of 
these cells. Thus for this reason, we believe SP is able to decrease 2H11 activation, 
especially after IR. SP may be able to normalize the tumor vasculature. Other studies in 
our lab have shown that SP was able to increase CD31 positive cells (marker for 
endothelial cells) and increase oxygenated hemoglobin in both xenograft and 
spontaneous breast tumors. The importance of increased vascularization and 
oxygenation can increase radiosensitivity of the tumor as well as increase delivery of 
chemotherapeutic drugs. Current studies are underway to combine radiation and SP in 
both animals and in vitro cultures to determine if there is increased cytotoxicity when SP 
and IR are combined.  
Comparisons of Human Biopsy Samples for Biopterin Metabolizing Enzymes 
 Although we saw mRNA differences between normal colonic epithelial cells and 
tumor cells in biopterin metabolizing enzymes, these data did not correlate well with 
protein expression or when compared with human colorectal samples. We believe this 
may be partly due to the CAC model we used. Due to the heterogeneity in size and 
stage of tumors, it may be difficult to ascertain differences. Thus plans for future studies 
include using biopsy material from human patients and a variety of tumor tissue and 
their normal tissue counterparts. We will also analyze biopterin metabolizing enzymes in 
MMTV Neu mice, which develop spontaneous breast tumors, to see if our results are 
generalizable in other tumor types. Lastly, we will see if by normalizing altered proteins 
in tumors, such as overexpressing SR or downregulating GFRP, can increase the 
BH4:BH2 in vitro in different tumor cells. These studies will elucidate further how tumor 
cells maintain a decreased BH4:BH2 ratio.   
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